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Summary
In this work, two projects were pursued.
In the first project, I investigated two different subtypes of opioid receptors, which
play a key role as target for analgesia. A set of subtype specific fluorescent ligands
for µ opioid receptor (MOR) and δ opioid receptor (DOR) was characterised and used
to gain insights into the diffusion behaviour of those receptors. It was shown that the
novel ligands hold photophysical and pharmacological properties making them suitable
for single-molecule microscopy. Applying them to wild-type receptors expressed in living
cells revealed that both sub-types possess a heterogeneous diffusion behaviour. Further-
more, the fluorescent ligands for the MOR were used to investigate homodomerisation,
a highly debated topic. The results reveal that only ≈ 5 % of the receptors are present
as homodimers, and thus the majority is monomeric.
G-protein coupled receptors (GPCRs) play a major role as drug targets. Accordingly,
understanding the activation process is very important. For a long time GPCRs have
been believed to be either active or inactive. In recent years several studies have shown,
that the reality is more complex, involving more substates. [1, 2, 3, 4] In this work the
α2AAR was chosen to investigate the activation process on a single-molecule level, thus
being able to distinguish also rare or short-lived events that are hidden in ensemble mea-
surements. With this aim, the receptor was labelled intracellular with two fluorophores
using supported membranes. Thus it was possible to acquire movies showing qualita-
tively smFRET events. Unfortunately, the functionality of the used construct could not
be demonstrated. To recover the functionality the CLIP-tag in the third intracellular
loop was replaced successfully with an amber codon. This stop codon was used to insert
an unnatural amino acid. Five different mutants were created and tested and the most
promising candidate could be identified. First ensemble FRET measurements indicated
that the functionality might be recovered but further improvements would be needed.
v
Overall, I could show that single-molecule microscopy is a versatile tool to investigate
the behaviour of typical class A GPCRs. I was able to show that MOR are mostly
monomeric under physiological expression levels. Furthermore, I could establish intra-
cellular labelling with supported membranes and acquire qualitative smFRET events.
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Zusammenfassung
In dieser Arbeit wurden zwei Projekte verfolgt.
Im ersten Projekt wurden zwei Subtypen der Opioidrezeptoren untersucht, die eine
wichtige Rolle fu¨r die Wirksamkeit von Analgetika spielen. Ein Set von subtypspez-
ifischen fluoreszierenden Liganden fu¨r den MOR und den DOR wurde charakterisiert
und eingesetzt, um Einblicke in das Diffuionsverhalten der Rezeptoren zu gewinnen.
Es konnte gezeigt werden, dass die neuartigen Liganden sowohl photophysikalische als
auch pharmakologische Eigenschaften besitzen, die sie fu¨r die Einzelmoleku¨lmikroskopie
interessant machen. Versuche mit Opioidrezeptoren, die in lebenden Zellen exprim-
iert werden, zeigten, dass beide Subtypen heterogenes Diffuionsverhalten aufweisen.
Des Weiteren wurden die fluoreszierenden Liganden fu¨r den MOR genutzt um Homod-
imerisierung zu untersuchen, da dies ein kontrovers diskutiertes Thema ist. Die Ergeb-
nisse zeigen, dass lediglich ≈ 5 % der Rezeptoren als Homodimere vorliegen und der
Großteil monomerisch ist.
GPCRs sind besonderem Interesse, weil sie Angriffspunkt vieler Medikamente sind.
Deshalb ist es wichtig ihren Aktivierungsmechanismus besser zu verstehen. Lange Zeit
wurde angenommen, dass GPCRs entweder aktiv oder inaktiv sind. Neuere Studien
zeigten jedoch, dass die Realita¨t komplexer ist und der Prozess Zwischenschritte in-
volviert. [1, 2, 3, 4] In dieser Arbeit wurde der α2A Adrenorezeptor als prototypischer
Klasse A GPCR gewa¨hlt, um den Aktivierungsprozess auf Einzelmoleku¨llevel zu unter-
suchen. Durch die Betrachtung einzelner Rezeptoren ist es mo¨glich auch seltene oder sehr
kurzlebige Ereignisse zu unterscheiden, die in Kollektivmessungen untergehen. Um dies
zu erreichen wurde der Rezeptor erfolgreich intrazellula¨r mit zwei Fluorophoren markiert.
Dies gelang durch die Herstellung von “supported membranes”, also Zellmembranen die
auf einem Objekttra¨ger fixiert wurden. Dadurch war es mo¨glich Videos aufzunehmen,
die Einzelmoleku¨l-FRET-Ereignisse zeigen. Jedoch gelang es nicht zu zeigen, dass der
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Rezeptor als Ganzes noch funktional war. Um einen funktionalen Rezeptor zu erhalten,
wurde das CLIP-Tag in der dritten intrazellula¨ren Schleife erfolgreich durch ein Stop-
codon ersetzt, welches fu¨r eine nicht kanonische Aminosa¨ure kodierte. Fu¨nf verschiedene
Mutanten wurden kloniert und getestet, wobei der vielversprechendste Mutant identi-
fiziert werden konnte. Erste FRET-Kollektivmessungen deuten darauf hin, dass dieser
Mutant funktional sein ko¨nnte. Jedoch sind weitere Verbesserungen no¨tig.
Insgesamt konnte ich zeigen, dass Einzelmoleku¨lmikroskopie vielseitige Mo¨glichkeiten
bietet um das Verhalten von GPCRs zu untersuchen. Ich konnte nachweisen, dass MOR
unter physiologischen Bedingungen hauptsa¨chlich als Monomere vorliegen. Des Weiteren
konnte ich Dank supported membranes die Markierung durch Farbstoffe im Intrazellu-
larbereich etablieren und qualitative smFRET Ereignisse aufnehmen.
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1. Introduction
1.1. GPCR’s and their physiological role
GPCRs constitute the largest super family of membrane receptor and are encoded by
over 800 genes in the human genome. They are implicated in the sensation of light,
taste and smell and they are the receptors for several hormones and neurotransmitters.
Furthermore, they play a crucial role in many physiological processes, like pain trans-
mission, and are implicated in several diseases like Alzheimer and schizophrenia amongst
others. For this reason, 34 % of all drugs on the market act on GPCRs. These comprise
475 drugs acting on just 108 of the non-olfactory GPCRs. [5] This implies there is an
ample market and large need for more research on GPCRs to improve existing drugs
and to find and develop new compounds as well.
All GPCRs share major common structural features: they comprise seven transmem-
brane helices linked by three extracellular loops and three intracellular loops (ICLs).
The N-terminus is located extracellularly, whereas the C-terminus is in the cytosol, both
differing in length depending on the receptor. Recently, more and more structures were
solved especially using x-ray crystallography, and even more recently cryo electron mi-
croscopy (EM). [6, 7, 8] The structure is closely linked to the receptor function. Thus,
more insights in the structure can provide a better understanding of the functionality,
especially with structures of the same receptor in different conformation states. The
structure of a prototypical class A GPCR is shown in figure 1.1.
GPCRs are grouped into 6 different classes based on similarities among their struc-
tures. The first and biggest class, class A, is formed by rhodopsin-like receptors (over
700 members). The secretin family, class B, contains 15 members whereas the adhesion
family has 24 members. Class C, the glutamate family, is formed by 15 members. The
last class present in vertebrates is class F, containing frizzled and taste receptors (24
members). [10, 11] Class D and E do not occur in vertebrates.
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Figure 1.1.: Molecular structure of the µ opioid receptor. Shown is the molecular structure
of the µ opioid receptor bound to an antagonist (pink) as representative for the
general structure of GPCRs. The seven helices spanning the membrane are charac-
teristic for GPCRs. Based on the crystal structure from Manglik et al. [9] (PDB:
4DKL)
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1.2. The activation mechanism of GPCRs
For a long time, it was thought that GPCRs essentially exist in two distinct states: active
and inactive. [12, 13] In recent years, however, more and more evidence accumulated
that the nature of GPCRs is more complex. It is hypothesised that GPCRs have several
conformational substates between which they are switching back and forth. [1, 2, 3, 4]
Upon ligand binding to the orthosteric site, which is extracellular, a conformational
re-arrangement is triggered. Depending on the receptor and the ligand, the first con-
formational changes are rather slight, e.g. a small turn of a side chain or a twist of a
transmembrane helix. Those re-arrangements at the extracellular side cause movements
within the receptor, propagating to its centre and further to the intracellular side, where
the half of transmembrane segment 6 (TM6) facing the intracellular side, is moving out-
wards by about 14 A˚. [6] A smaller movement in form of a rotation is observed for the
intracellular end of transmembrane segment 7 (TM7), involving the conserved NPxxY
motif. [14] This re-arrangement leads to the formation of a binding pocket for the G
protein is. The binding of the G protein stabilises the active conformation of the receptor
by lowering the free energy of this state in comparison to the inactive state. [14, 15, 16]
The receptor can freely switch between different substates ranging from fully inactive
to inactive through partially active to fully activated, or even more substates. [4, 17, 14]
This can explain why a basal activity can be observed for several receptors. In absence
of a ligand and nucleotides the inactive states are more likely to be found as their free
energy is lower than that of active conformations (as shown in figure 1.2). [14, 4] Lig-
ands have the ability to modulate the free energy levels of the different substates through
chemical interactions and, thereby, change the probabilities of finding the receptor in
the different substates. [14, 4, 18] For example, an agonist lowers the free energy of
the activated state in comparison to the inactive conformations. An inverse agonist on
the other hand would lower the free energy of the inactive state further and/or increase
the one of the activated states and in consequence decrease the probability of activated
receptors. [19]
Lamichhane et al. ([17]) used single-molecule fluorescence imaging on the β2AR em-
bedded in phospholipid nanodiscs. [17] They showed that the receptor spontaneously
switches between two distinct conformational states, which they assigned to an inactive
3
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Figure 1.2.: Energy landscape of different substates. A schematic representation of the effects
of different ligands and nucleotides on the free energy of the receptor and how
this leads to different probabilities to find the receptor in certain conformations.
Adapted from [14]
and active-like receptor conformation. Under basal condition, the inactive form was more
likely to be present whereas after treatment with a full agonist the receptor favoured
the active conformation. In line with this, an inverse agonist changed the probability in
favour of the inactive conformation. [17]
The activation process of GPCRs can be monitored with different biophysical meth-
ods and/or biochemical essays. The most direct way is to look at the conformational
changes at the intracellular side of the receptor itself, while most of the assays focus
on downstream changes and signals following the activation (e.g. radioactive GTPγS
binding assay, calcium assay [12, 20]). With direct approaches, it is not only possible to
investigate the amplitude of the conformational changes necessary for the activation, but
also to determine the activation speed. The fastest known activated GPCR is rhodopsin,
which is activated within milliseconds. [21] For this prototypical GPCR the conforma-
tional changes are triggered by the absorption of a photon which causes an isomerisation
of the retinal from 11-cis to all-trans. [22] In comparison to rhodopsin, Vilardaga et al.
([23]) investigated two GPCRs that are activated by binding of ligands: the α2AAR, a
class A GPCR, and the parathyroid hormone receptor (PTHR), belonging to class B.
[23] In this study, cyan fluorescent protein (CFP) and yellow fluorescent protein (YFP)
were cloned into the third ICL and the C-terminus, respectively, using the fluorophores
as FRET pair. After stimulation with the respective ligand, an activation time constant
of ∼ 40 ms was observed for the α2A adrenergic receptor (α2AAR ) and ∼ 1 s for the
PTHR. [23] Further studies by different groups showed that various class A GPCRs
have an activation speed in the range of 30 − 50 ms. [24, 25, 26]
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The ligand induced conformational changes enable the receptor to function as a
guanine nucleotide exchange factor (GEF) for the G protein. More precisely, the receptor
stimulates the exchange of guanosine diphosphate (GDP) for guanosine triphosphate
(GTP) on the Gα subunit. This exchange triggers the dissociation of the G protein
complex from the active receptor and the dissociation of the Gα subunit from the Gβγ
dimer. The Gα and Gβγ subunits then act as effectors for intracellular second messenger
cascades and therefore continue the signal transmission from an extracellular stimulus
to an intracellular signal. The bound GTP is hydrolysed to GDP. This hydrolysation
inactivates the Gα subunit, causing it to re-associate again with the Gβγ dimer. The
inactive trimeric G protein can in turn bind to a receptor awaiting a new activation
round. A scheme of the activation cycle is shown in figure 1.3. [27, 28, 29, 13]
Still a highly debated question in the field of GPCR research is whether the G protein
just binds when a ligand has bound to the receptor, or if the receptor and the G protein
can pre-couple without ligand binding. The latter is also known as the ’ternary complex
model’. [30, 31, 32, 33] The ternary complex model is in good agreement with the idea
that the free receptor can switch between an active and inactive conformation. Only
if the receptor is present in the active conformation, i.e. the TM6 is moved outwards,
pre-coupling can occur and thus might lead to basal activity of some receptors.
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Figure 1.3.: Scheme of the GPCR activation cycle. Depicted is the activation cycle of a proto-
typical GPCR. A) Unbound GPCR pre-coupled to the heterotrimeric G-protein.
The TM6 (orange helix) is inside. In B), the ligand (red triangle) is bound and the
TM6 is moving outward. GDP is released and thus the nucleotide free high affinity
ternary complex is present. C) The high amount of available GTP leads to the
binding the Gα subunit and sub-sequentially to the dissociation of the G-protein
itself (D). The activated Gα subunit and the Gβγ can now interact with further
effectors. E) the GTP will be hydrolysed to GDP, giving way to the re-association
of the Gβγ with the Gα subunit (F).
6
1.3. GPCR dimerisation
1.3. GPCR dimerisation
GPCRs interact with a multitude of other molecules like ligands, G-proteins, β-arrestins
and other effectors. An abundance of studies has shown that GPCRs can also interact
with each other and form dimers or even higher order oligomers. [34, 35, 36, 37, 38]
For class C GPCRs, like the γ-aminobutyric acid type B (GABAB), it was even shown
that they can be obligatory heterodimers. [39, 40, 41] Class A GPCRs seem to be more
heterogeneous as there are controversial findings regarding their prevalence as monomer
or dimers. [37, 42, 38, 36, 43] The differences between studies, even for the same re-
ceptor, could be explained by the variety of methods that are applied for the investiga-
tion of dimerisation ranging from co-immunoprecipitation to FRET and bioluminscence
resonance energy transfer (BRET) assays, to single-molecule fluorescence microscopy
techniques and fluorescence correlation spectroscopy (FCS), or even computational sim-
ulations. [44, 45, 46, 43, 47] In addition, the studies often differ in the system they use,
like transiently transfected cells (with different expression levels), purified receptors or
native tissues. [48, 49, 50]
The investigation of dimerisation could give more insights into the underlying mecha-
nism of how one ligand can trigger different signal responses. It has already been shown
that dimerisation influences the pharmacological properties of receptors and ligands for
example for the opioid receptors. [51, 49, 52] The heterodimerisation of MOR and DOR
has been suggested to lead to a faster internalisation of both receptors, whereas the MOR
does not internalise upon morphin stimulation. [53] Furthermore, the stoichiometry of
monomers and dimers can be influenced by the application of different ligands. Tabor
et al. could show an increase in dimer formation upon agonist binding for the dopamine
receptor, while the application of an antagonist did not differ the fraction of dimers in
comparison to ligand free receptors. [37] A better understanding on how the receptors
interact, and how the downstream signalling is affected could help to develop drugs that
act more specifically and may reduce side effects.
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1.4. Opioid receptors
The group of opioid receptors consists of four members: the MOR and κ opioid recep-
tor (KOR) were the first ones to be found and named after their prototypical ligands mor-
phin and ketocyclazocine, respectively. [54] The DOR and nociception receptor (NOR)
were discovered later. [54] All four belong to the rhodopsin-like class A of GPCRs.
Overall the MOR, DOR and KOR show more homology towards each other than to the
NOR. [55, 56] This is reflected in the ligand affinity of the NOR, which appears to be
very limited for morphine-like compounds and opioid peptides. [57] On the other hand,
the classical group of opioid receptors (MOR, DOR and KOR) show low affinities for
the endogenous ligand of NOR, nociceptin.
Opioid receptors are widely expressed in the brain, spinal cord, digestive tract and in
peripheral sensory neurons. They are widely known for their analgesic effect and there-
fore play a major role as a drug target for pain killers. Furthermore, opioid receptors
are well known for their recreational effects. The opium poppy, papaver somniferum,
has been used for thousands of years as agricultural crop. The first written report of the
production of pharmaceutical compounds out of the seeds dates back to 4000 b.c.. [58]
In modern medicine, opioids still play a big role with drugs on the market like Oxycodon,
Codeine and Tilidin to name just a few. On the illegal drug market, Heroin proves to
be a big problem. [59] Since the 90’s, North America is struggling with the so termed
’opioid crisis’, which causes more and more deaths by overdose. [60] Often addictions
start with a prescription of opioids for medical reasons, leading to craving of more opi-
oids as a side effect. To prevent addictions and overdoses safer and better opioid drugs
are needed. [61, 62, 60] Hence, it is no surprise that opioid receptors and especially
the MOR are subject of intense research ranging from the synthesis of new ligands over
structural analysis to pharmacological studies and computational simulations.
Opioid receptors are coupled to the inhibitory G-protein (Gi) and after activation
of the receptor, the βγ-complex of the G-protein binds to the Voltage-gated dependent
calcium channel (VDCC). This causes an inhibition of the calcium channels and thus
decreases the influx of calcium ions into the neuron. The calcium influx is required
for the fusion of synaptic vesicles and the release of neurotransmitter. In addition, the
βγ-complex binds to potassium channels as well, causing their opening, which leads to
an increase of potassium ions. Taken together, these modifications of ion input to the
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neuron causes a hyperpolarisation leading to the reduction of neurotransmitter release.
The release of neurotransmitters from the pre-synaptic site, such as glutamate, causes
the activation of AMPARs and other receptors at the post-synaptic site. In this way the
sensation of pain can be transmitted from the primary neuron to the secondary neuron.
By reducing the release of neurotransmitter, opioids can act as effective analgesia as the
pain transmission is reduced directly. A schematic representation of pain transmission
is shown in figure 1.4.
The first crystal structure of MOR was published by Manglik et al. in 2012 bound
to β-funal- trexamine (β-FNA), which is an irreversible morphinan antagonist. [9] The
receptor crystallized in parallel dimers, with contacts through transmembrane (TM) he-
lices 5 and 6, and in a more limited way through TM helix 1, 2 and 8.
The question whether opioid receptors exists in monomers, hetero- or homodimers is still
under debate, with some studies favouring monomers [63, 64] whereas in other studies
dimers are observed [65, 66, 51, 67, 45, 68, 69]. In 1997, Cvejic and Devi could show
that the DOR forms dimers and the ratio of homodimers to monomers can be alternated
by agonist stimulation, leading to a decrease of dimers. [65] Two years later, Jordan
and Devi published biochemical and pharmacological results for the heterodimerisation
of the δ and κ opioid receptors. They also found evidence for different pharmacological
behaviour of the heterodimer in comparison to the monomers. [35] This was further
confirmed by a follow-up study from the same group in 2000, showing that for MOR
and DOR heterodimers, δ subtype-specific ligands can lead to an increase in binding of
µ agonist. [66, 51] The levels of µ− δ heterodimers at the cell surface can be regulated
by a Golgi chaperone (RTP4). [70] Furthermore, Gomes et al. confirmed the presence
of homodimers of the µ subtype using BRET assays in living cells. [67]
Wang et al. also used BRET to investigate hetero- and homodimerisation of all three
classical subtypes of opioid receptors, e.g. MOR, DOR and KOR. [45] They showed
that the dimerisation happens before trafficking of the receptors to the membrane occurs
and that all sub-types have similar affinities for the formation of dimers, regardless if the
same sub-type (homodimers) or with a different sub-type (heterodimers). In addition to
BRET, they also performed co-immunoprecipitation, receptor binding, and G protein
coupling assays in their comprehensive study. [45] In 2002, He et al. investigated the
effects of oligomerisation on the trafficking of MOR using a wild-type MOR receptor
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with FLAG-tag and a human influenza hemagglutinin (HA)-tagged D MOR, which is a
chimera of MOR where the tail is replaced by the tail of the DOR. [53] Upon stimulation
with morphine they observed internalisation of both receptors. Wild-type MOR alone
does not internalise upon morphine stimulation, hence they concluded that the D MOR
is dragging the wild-type MOR into the endocytosis. This effect was shown in human
embryonic kidney (HEK) 293 cells as well as in cultured neurons [53]
In 2009 Kuszak et al. expressed a MOR variant fused to a YFP in insect cells.
[63] Single-particle imaging suggested that MOR function as monomers, which was also
confirmed by using fluorescent ligands, labelled with Cy3, as well as for single-particle
imaging giving the same result. Hence they claimed that oligomerisation is not needed
for receptor function. [63] By performing coarse-grained (CG) molecular dynamics (MD)
simulations with opioid receptors, Provasi et al. showed the formation of homo- as well
as heterodimers for all three sub-types. [68] Once they observed a dimer formation
there were just minor adjustments at the interfaces but no dissociation events within
their 10µs simulations. [68] Another study using CG MD simulations was published by
Zhang et al.. [69] They looked at the role of the different conformational states of the
two MOR protomers forming a homodimer. The simulations gave hints for both, posi-
tive and negative, co-operativity for the activation of the protomers. The dimerisation
also influences the structural communication pathways from the ligand binding region
to the G-protein binding site of the inactive protomer. The influence and importance of
dimerisation on downstream signalling still needs to be investigated. [69] In a very recent
study, Meral et. al used MD simulations to look at the dynamics of MOR homodimers
and verified their findings with FRET acceptor photobleaching experiments both giving
way for negligible fractions of homodimers at physiological conditions. [64]
These controversial findings obtained with various methods indicate that the answer
to the question whether opioid receptors form dimers is rather complex. Nevertheless the
answer can give important insights into the functionality of the receptors and especially
whether the pharmacological function is alternated upon homo- or heterodimerisation.
Better knowledge about this mechanism could pave the way for the development of im-
proved drugs.
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Figure 1.4.: Schematic representation of pain transmission. The afferent primary neuron trans-
mits the nociceptive stimuli to the post-synaptic glutamatergic neuron by releasing
glutamate activating AMPARs on post-synaptic neurons. If opioids are released
by an efferent opioidergic neuron they cause the activation of the inhibiting G-
protein, leading to an outflux of potassium in the post-synaptic side causing a
hyperpolarisation. At the pre-synaptic side Ca-channels are inhibited, leading to
a decrease of calcium influx and thus inhibits the fusion of synaptic vesicles and
neurotransmitter release. Adapted from Graefe, Duale Reihe Pharmakologie und
Toxikologie.
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1.5. Single-molecule microscopy and its applications
1.5.1. Single-molecule microscopy and its requirements
For decades GPCRs have been investigated using ensemble measurements averaging over
hundreds to thousands of receptors. Notwithstanding this brought a lot of knowledge
and insights into the field, those ensemble measurements also have their drawbacks. Rare
events and heterogeneous behaviours might be obscured, short-lived states averaged out
by longer ones. Single-molecule approaches help to overcome those limitations. As they
allow to study each single event individually there is no need for averaging and therefore
making rare and transient events visible. Furthermore, there is no need of synchronisa-
tion, as it is for ensemble measurements with ligand stimulation, for example. [71, 72]
In the case of single-molecule imaging, the resolution in time and space is approaching
the millisecond and nanometer scale respectively, allowing to investigate heterogeneous
diffusion behaviour. [73] The size of molecule complexes is another question that can be
addressed by single-molecule imaging, even in living cells as there is no need to break
down the cell and therefore the methods are less prone to artefacts. [38] Maybe most im-
portantly they give way to studies of the dynamics of protein-protein and protein-ligand
interactions, for example to calculate association and dissociation rates. [73, 38, 74]
To achieve single-molecule imaging, the protein of interest (POI) is normally fluores-
cently labelled (see section 1.6). The so attached fluorophore needs good photophysical
properties like a) efficient absorption of light, b) a high quantum yield so that there are
enough photons to be detected, c) having a high photostability to allow long observa-
tions before photobleaching occurs and d) rare blinking, so that the fluorophore does not
go into a dark state. The latter is crucial for example in single-particle tracking (SPT)
experiments. In this case, the blinking would lead to an interruption of detection and
therefore break a long trajectory into two shorter ones. In other approaches the blinking
behaviour of fluorescent probes can also be taken as an advantage, which is done for
example in stochastic optical reconstruction microscopy (STORM).
Furthermore, the receptors need to be sufficiently separated in space for single-molecule
microscopy. That means the separation needs to be higher than the Abbe diffraction
limit which is about 200 nm for visible light and defined by:
12
1.5. Single-molecule microscopy and its applications
d =
λ
2n sin Ω
=
λ
NA
(1.1)
where λ is the wavelength and NA the numerical aperture. Due to this diffraction limit
the single fluorophore will appear as a blurry disc. By fitting it with a two-dimensional
Gaussian distribution the localisation of the centre of the spot can be accurately deter-
mined in a range of 10 − 30 nm, as shown in figure 1.5 B. [71] The localisation precision
depends on the number of collected photons, N :
σ =
√
s2 + a
2
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N
(
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(1.2)
where a2 is the pixel area of the detector, b2 is the average number of photons of the
background and s is the standard deviation of the point spread function (PSF). This
correlation shows that there are two ways of improving the localisation precision. One
was already mentioned above, to use fluorophores with a high quantum yield, thus in-
creasing the number of photons that can be detected. Another way is to improve the
signal-to-noise ratio, e.g. minimising the background.
Fluorescence from the background can be reduced by using TIRF microscopy. In this
case, the excitation light, typically a laser beam with a specific excitation wavelength,
is entered in an over-critical angle into a prism, causing the effect of total internal
reflection. The thus reflected light creates an evanescent wave, penetrating the spec-
imen/probe (see scheme in figure 1.5 A). The electromagnetic field of the evanescent
wave decays exponentially, leading to a penetration depth of just about 100 nm. This
allows to image everything that is close to the objective, where the evanescent wave is
created, with high precision, while everything beyond this area appears dark and does
not contribute to the background. In the range of the evanescent wave typically lies
the basal membrane of cells, allowing imaging of receptors on and within the membrane
with high precision.
In combination with high speed electron-multiplying charge-coupled device (EMCCD)
or complementary metal-oxide-semiconductor (CMOS) sensors as detectors, the tempo-
ral resolution can also be improved up to a few µs only, which is crucial for the investi-
gation of dynamic processes.
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Figure 1.5.: TIRF, single-particle detection and tracking. A) shows the principle of total in-
ternal reflection fluorescence (TIRF) microscopy. In B) a representative blurred
fluorescent spot from TIRF imaging is shown and how a 2D Gaussian fitting is ap-
plied. C) depicts the detection of single-particles over time in consecutive frames.
The following tracking and linking is shown in D).
1.5.2. Single-particle detection and tracking
Employing those single-molecule microscopy techniques generates a tremendous amount
of data, which needs to be analysed accordingly. This lead to the development of au-
tomated SPT algorithms. The first step in SPT is always the detection of the single-
particles. As mentioned before, a two-dimensional Gaussian is fitted to the fluorescent
spot and the centre is thus localised. This is done for each single frame of the movie.
The next step is to determine which detected particle in frame f is the same particle
in frame f + 1. With the assumption that the particle can just travel a certain dis-
tance within ∆t, the time between two frames, a search radius is defined and adjusted
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according to the experimental parameters. The particle trajectories are built by linking
the localised particles from one frame to the other, a schematic representation of de-
tection and tracking is shown in figure 1.5 C and D. The algorithms have to take into
account particle splitting and merging events like in complex formation, dissociation and
in protein-protein interactions. In addition, particles can be dark for a few frames, for
example because of blinking, despite this the algorithm should be capable of linking the
trajectories correctly. Aside from those difficulties, receptors in living cells show hetero-
geneous diffusion behaviour. The expression level of receptors can also be challenging,
as higher densities make the correct assignment and tracking more difficult.
To address all those issues, Jaqaman et al. developed a robust single-particle tracking
algorithm which calculates the overall cost of each linkage to approach the optimal so-
lution, which would be Multiple-hypothesis tracking (MHT). [75, 76] The problem with
MHT is, that it would be too greedy for computational analysis even for a small number
of particles. Therefore it can only be approached by either searching the temporal, or
the locally optimal solution for tracking. Jaqaman et al. tackled all challenges of SPT
at once with their algorithm by using the linear assignment problem. The initially de-
tected particles are linked between consecutive frames and afterwards the so obtained
trajectory fractions are linked, also taking merging and splitting events and the closure
of gaps into account. In their algorithm, a ’cost’ is calculated for each linkage and event,
and the overall cost is then optimised, resulting in a solution with the lowest cost, which
represents the most likely tracking. This leads to a global optimisation in space and
time comparable to MHT. [75]
1.5.3. The quest of explaining diffusion
The single trajectories can then be further investigated for example to obtain insights
into the diffusion behaviour of particles in and on the cell surface. To determine the
form of motion present, the mean squared displacement (MSD) is calculated.
MSD =
〈[
x(t) − x(0)]2〉 = 1
N
N∑
n=1
[
xn(t) − xn(0)
]2
(1.3)
where N is the number of particles, over which the average is taken, xn(0) = x0 is
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the initial position of each particle and xn(t) is the position of each particle at time
t. Thus it is possible to calculate the average diffusion behaviour of particles in a cell,
for example. In case of single-particles the MSD is averaged over time, therefore it is
called time-averaged mean squared displacement (TAMSD), making it possible to get
information about the diffusion behaviour of single trajectories. By applying TAMSD,
different groups were able to show very heterogeneous diffusion behaviour ranging from
virtually immobile particles, to sub-diffusive motion, to normal diffusion or even super-
diffusive behaviour. To distinguish between these different forms of motion it has been
shown to be advantageous to look at the anomalous diffusion factor α as schematically
shown in figure 1.6, but also other methods for classification have been used. [77] In
contrast to normal diffusion, anomalous diffusion follows a power law dependence
MSD ' D · tα (1.4)
Virtually Immobile
Super-Diﬀusion
α>1
Normal Diﬀusionα=1
Sub-Diﬀusion
α<1
Time (s)
M
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Figure 1.6.: MSD and diffusion categories. Schematic graph of mean squared displacements
(MSD) for different types of motion: virtually immobile (black), sub-diffusion
(red), normal diffusion (blue) and super-diffusion (green).
with D as diffusion coefficient. If α = 1 it is normal diffusion. Every trajectory with
α > 1 is called super-diffusion, which requires more then just random forces. Trajec-
tories with α < 1 are called accordingly sub-diffusion, in which case the membrane is
crowded and the receptor faces some obstacles which makes it more difficult to explore
the space. [78] The reasons for the deviation from normal diffusion can be numerous,
ranging from the lipid environment of the particles to protein-protein interactions, to
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physical barriers like the cytoskeleton. In 2005 Suzuki et al. showed that MORs la-
belled with gold spheres in living cells can jump between neighbouring compartments.
[73] Within the compartments the receptors were confined until they overcame the bar-
rier to the next compartment. This led to the formulation of the ’fence-and-picket’
model. The cytoskeleton, like actin fibers, is represented as fences, and the membrane
proteins, anchored to the cytoskeleton, are acting like pickets. Together these structures
act as barriers limiting the diffusion and leading to an observed confinement. [73, 71].
1.5.4. Investigating protein complexes using single-molecule
imaging
Single-molecule imaging techniques can also be used to investigate the size of complexes,
e.g. how many molecules the complex comprises and the dimerisation of receptors (see
section 1.3). [38, 37, 79] Therefore the fluorescent intensity of the detected spots is anal-
ysed and compared to the intensity of single fluorophores. As expected, monomers have
the same intensity profile as a single fluorophore, dimers have double the intensity etc..
Furthermore, it is possible for long enough observations to simply count the bleaching
steps. By looking at the fluorescent intensity of complexes it was possible to compare
three different prototypical GPCRs: β1 adrenergic receptor (β1AR), β2 adrenergic recep-
tor (β2AR ) and GABAB. The β1AR showed the least degree of dimerisation and mostly
stayed monomeric whereas GABAB showed a high degree of oligomerisation, which can
be expected as it is a constitutive dimer. [38, 11, 40, 41]
In the case of the dopamine receptor, Tabor et al. were able to show that the binding
of ligands can change the ratio between monomeric and dimeric receptors, whereas the
application of an antagonist did not change the ratio in comparison to unbound recep-
tors. [37] As discussed earlier, the formation of dimers can play an important role for
the pharmacology of GPCRs. Using single-molecule approaches to study the formation
and the size of receptor complexes can give new and more insights in the dynamics,
and is less prone to artefacts as there is no need of cell disruption as for example in
co-immunoprecipitation.
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1.5.5. Single-molecule FRET
Single-molecule imaging techniques can be combined with Fo¨rster resonance energy
transfer (FRET), which is also known as ’molecular ruler’. [80, 81] It is a fluorescence-
based technique with two fluorophores, a donor and an acceptor. The latter is red-shifted
in comparison to the donor and can be used for measuring distances in the range of
1− 10 nm. [81] The so called FRET-pair has to be chosen wisely, as the donor emission
and acceptor excitation spectrum need to have some overlap to give efficient FRET ratios
(see figure 1.7). On the other hand, both fluorophores need to be spectrally separated
so that effects like bleed-through and cross-excitation are minimized. [82, 83]
FRET is a dipole-dipole coupling mechanism and its efficiency E is sensitive to the
distance r between the two fluorophores:
E =
1
1 + (r/R0)6
(1.5)
where R0 is called the Fo¨rster distance, which is specific for each donor-acceptor-pair
and the orientation they have towards each other and is defined by:
R0 = 0.211
(
κ2n−4QDJ(λ)
)1/6
(1.6)
with QD, the fluorescence quantum yield of the donor, κ
2 is the dipole orientation
factor, n the refractive index of the medium and J(λ) is given by the spectral overlap of
the donor emission and the acceptor excitation spectrum. [84, 85, 82]
As shown in eq. (1.6), FRET is highly sensitive to even subtle distance changes
(inverse 6th power law) and this in a range that cannot be resolved by common single-
molecule imaging approaches. Thus the combination of both methods can give more
insights into dynamic processes for intra- as well as for inter-molecular complexes. In re-
cent years, this approach was also used for the investigation of GPCRs. Vafabakhsh et al.
used single-molecule fluorescence resonance energy transfer (smFRET) on metabotropic
glutamate receptors (mGluRs), dimeric class C GPCRs which have a large extracellu-
lar ligand binding domain (LBD). They showed that the LBD switches between three
conformations: resting, a short-lived intermediate, and an active state. The transitions
between those conformations can be alternated by ligands and in case of mGluR3 also
by Ca2+. [86]
Gregorio et al. applied smFRET on immobilised β2AR mutants in a comprehensive
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Figure 1.7.: FRET spectra. Shown are the excitation (dashed line) and emission (filled) spectra
of Alexa Fluorophore 546 (left) and Alexa Fluorophore 647 (right).
study. The receptors were labelled with optimised Cy3B and Cy7 as FRET-pair to com-
pare the efficacy of different ligands ranging from neutral antagonist and inverse agonist
to partial agonist and full agonist. They observed shifts in the FRET efficiencies as
well as in the full-width at half maximum (FWHM) values for the different conditions.
Furthermore, they were able to investigate the formation of β2AR−Gs complexes and
to show that the presence in a low FRET state, which is interpreted as activated and
Gs bound, is correlated with the efficacy of the ligand. In addition, Gregorio et al. mea-
sured the effect of nucleotides on the dissociation of the β2AR−Gs complexes. In the
presence of nucleotides the complexes stay for multiple seconds whereas they dissociate
ca. twofold faster in the presence of GTP. [18]
Dijkman et al. combined smFRET with other methods to get more insights into the
dynamics of dimer formation. They studied purified neurotensin receptor 1 (NTS1),
labelled with Cy3 and Cy5, and reconstituted them into DPhPC droplet interface bilay-
ers with a receptor density similar to physiological conditions. Thus, they were able to
visualise the formation of individual dimers, and in combination with the results from
other techniques, proposed a ’rolling-dime’ interface model, meaning that different dimer
conformations can exist and interchange. [44]
These recent studies show that smFRET can serve as a helpful addition to more estab-
lished methods and give more insights into dynamic processes like receptor activation
and dimerisation, but it can also be used for pharmacological studies about efficacies,
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for example. As all previous described studies were performed on purified receptors, an
important and missing step forward for smFRET is its application in living cells.
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1.6. Different labelling strategies
As described earlier (section 1.5.1) it is necessary for the application of imaging tech-
niques, to make the POI visible. This is usually achieved by introducing a fluorescent
reporter probe. Over the past decades different approaches have been reported. [72, 87]
Out of those, three were used in this work and are depicted in figure 1.8.
Crucial questions for the introduction of fluorescent probes are where it is located within
the receptor, the kind of probe used and also how it should be introduced. All these
factors could have an impact on the functionality and/ or expression of the receptor and
lead to significant differences in comparison to the wild-type receptor. [88, 72]
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Figure 1.8.: Schemes of different labelling techniques. A) shows the SNAP-tag technique, where
the fluorophore is bound to a BG substrate. B) depicts the usage of unAA for
click labelling. In C) the labelling via a fluorescent ligand is shown.
1.6.1. Labelling via SNAP- and CLIP-tag
Site-specific labelling is crucial for the investigation of dynamic processes in GPCRs
or other POIs. Using gen-editing it is possible to insert a fluorescent protein (FP)
at specific sites, such as green fluorescent protein (GFP) derivatives. This technology
has shown to be versatile in different applications and also lead to the development
of biosensors/FRET-sensors like Epac1. [20, 89, 90, 91] Nevertheless FPs have some
limitations. One disadvantage of FPs is that not all become fluorescent or are even
correctly folded but for single-molecule studies of interactions or oligomerisation it is
necessary to have a high labelling efficiency. [38, 92, 72] Small organic fluorophores are
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also more photostable than FPs, giving way for longer observations. In addition, the
insertion of a tag, which is labelled just before the experiments, allows for more flexibility
in choosing the fluorophore. [92, 72, 93, 94] This requirement led to the development of
self-labelling protein tags amongst which the SNAP-tag, CLIP-tag and Halo-tag are the
most common one. [93, 95, 96]
Keppler et al. took advantage of the human deoxyribonucleic acid (DNA) repair protein
O6-alkylguanine-DNA alkyltransferase (AGT) which forms a covalent linkage with its
substrate BG. [93] The SNAP-tag can be incorporated into the POI and be expressed in
living cells. With a small organic fluorophore linked to BG a high labelling efficiency and
specificity is achieved. Since the technique was developed in 2003, a lot of fluorescent
probes have been engineered for the SNAP-tag technology, so that it is possible to select
the suitable fluorophore from a wide range of wavelengths. [97] A few years later, the
same lab developed a protein tag which can be labelled orthogonally to the SNAP-tag
allowing for multi-colour staining – the CLIP-tag. [95] This new tag was also derived
from the AGT, but in this case it has a substrate specificity with O2-benzylcytosin (BC).
With 19 kDa the SNAP- and CLIP-tag are smaller than GFP (27 kDa), for example,
and can be used for in vitro and real-time experiments. As the choice of fluorophores
is very flexible, it is possible to select those which fulfil the requirements for single-
molecule experiments. With the development of different, orthogonal tags even multi-
colour studies are in the realm of possibility. [38, 74, 98]
1.6.2. Labelling via unnatural amino acids
Even though the SNAP-tag is already smaller than FPs, an optimal protein tag would
be even smaller, and in the best case just one amino acid (AA). The problem with
site-specific labelling is that most of the amino acids are expressed on several sites, and
for this reason the POI must be genetically modified to have, for example, only one
cysteine left. The expanding of the genetic code by the use of unAA opens up a horizon
of possibilities. By introducing a 21st amino acid it is possible to choose nearly any site
within the POI, creating just a minor deviation from the wild-type protein and still be
very specific. As most of the codons are already translated to the 20 natural amino acids,
one of the three stop codons must be used for the introduction of an artificial amino acid
– opal or sometimes umber (UGA), ochre (UUA) or amber (UAG) (see figure 1.9). The
amber codon is the least frequent stop codon and it was already shown in E. coli that
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it can be suppressed efficiently. [99] Furthermore, the amber codon suppression is more
readily read through in comparison to opal and ochre in mammalian cells. [100] The first
successful incorporation of an unAA was achieved in 1989, when the amber codon was
translated to phenylalanine analogues. [101]. To achieve the successful incorporation
of an unAA, two different transfer ribonucleic acid (tRNA)s are required: one for the
suppression of the amber codon and one for the recognition and transfer of the unAA.
By applying a specific orthogonal aminoacyl-tRNA synthetase-tRNA it was achieved to
introduce an unAA into GPCRs in the recent years. [102, 103, 104, 105] The unAA
of choice needs to fulfil certain requirements for labelling. A promising approach is
bioorthogonal chemistry or click chemistry. [106, 107] The unAA contains strained
alkenes/alkynes which can then be labelled with an azide/tetrazine dye derivative.
These reactions are called strain-promoted alkyne-azide cycloaddition (SPAAC) and
strain-promoted inverse electron-demand Diels-Alder cycloaddition (SPIEDAC). They
are biocompatible, non-toxic reagents, and hence applicable to living cells. They react
specifically and fast in aqueous environments. [106, 108, 107]. As with SNAP- and CLIP-
tag, several dyes are available bearing the reactive group for SPAAC and SPIEDAC. In
addition, both are free of copper, which is commonly used for bioorthogonal labelling,
but can be toxic for living cells. Furthermore, SPAAC and SPIEDAC are orthogonal to
each other meaning they can be simultaneously used for two-colour labelling. [106, 109]
amber
UAG
ochre
UUA
umber
UGA
Figure 1.9.: The three stop codons in their colour representation: amber translated by UAG,
ochre by UUA and umber by UGA.
1.6.3. Labelling via fluorescent ligands
An approach of labelling GPCRs without the need of modifications on the POI is offered
by the use of fluorescent ligands. Here, endogenous or synthetic ligands are chemically
modified to transform them into fluorescent probes. This is usually achieved by conjugat-
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ing a dye via a linker to a known pharmacophore. The big advantage of this approach is
the possibility to investigate wild-type receptors even in living tissue. [110, 111] Caution
has to be taken as the chemical modifications can change the pharmacological properties
of the pharmacopohore. Therefore tests and comparisons to the parent compound are
advised. [72] Furthermore, the design and synthesis may not be straightforward, making
this approach sometimes laborious. Nevertheless, fluorescent ligands were already suc-
cessfully applied in different applications like binding assays, FRET-based binding stud-
ies in living cells and also for the investigation of receptor oligomerisation. [110, 111, 112]
If the fluorescent ligand has a high binding affinity to the POI it is suitable for single-
molecule imaging where high labelling efficacy is crucial. In addition it should have a
high specificity and some level of wash-resistance to reduce the fluorescent background.
It can then be used for studies of the receptor mobility on the membrane, oligomerisa-
tion and protein-protein interactions if the interaction partner is labelled as well. The
use of fluorescent ligands comes with some limitations as it interacts with the receptor
at the binding site. Depending on the ligand, it can act as an agonist or antagonist and
thus influence the behaviour of the receptor and might lead to faster internalisation,
for example. Furthermore, it limits the possibilities of dynamic interactions with other
ligands as the binding pocket is already occupied. In comparison to technologies like
SNAP-tag or the introduction of an unAA especially, the choice of binding site is limited
as ligands can only bind to the orthosteric or allosteric binding site.
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During this thesis two projects were pursued.
The aim of the first project was the characterisation of a set of novel subtype specific
ligands for the µ and δ opioid receptors. This included their pharmacological character-
isation as well as testing their applicability for single-molecule microscopy.
The new fluorescent ligands should be used to shed new lights on the dynamics of opioid
receptors. Until now there are conflicting finding about whether they form homodimers
or not. The dynamics of the receptors can have an impact on the downstream signalling,
thus a better understanding can lead to better and safer pain killers.
The use of the fluorescent ligands as tools for single-molecule microscopy techniques will
allow to investigate the dynamics of wild-type opioid receptors at the cell membrane.
Furthermore, they will be applied to to clarify if µ opioid receptors stay as monomers
or form homodimers, and if they form homodimers, to which extent.
The second project focused on understanding the activation process of α2AAR as pro-
totypical class A G-protein coupled receptor using single-molecule fluorescence resonance
energy transfer (smFRET). The establishment of smFRET in living cells should allow
the observation of short-lived and rare events and thus the investigation of heteroge-
neous dynamic processes. Thus it could serve to unravel the question if GPCRs exist
in only two states, inactive and active, or in more substates depending on the presence
and nature of ligands and coupling of G-proteins.
In order to succeed, first labelling of intracellular SNAP and CLIP-tags needs to be
achieved. Next, smFRET needs to be established at the lab. Afterwards, the recep-
tor could be tested in different environments, e.g. in the presence of different ligands
or nucleotides to favour different substates. Furthermore, data processing needs to be
established to draw conclusions from those types experiments. The findings should be
confirmed by ensemble FRET measurements, showing the functionality of the receptor
mutant bearing a SNAP- and CLIP-tag.
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3.1. Materials
,
3.1.1. Cell Lines
• Chinese hamster ovary (CHO)-K1 cells (#ACC 110 Leibnitz-Institut DSMZ)
• Human Embryonic Kidney (HEK)-293 A cells (ATCC)
• CHO α2A-CLIP-SNAP (Altair) cells (this work)
• CHO α2A-K327amb-SNAP (Bellatrix) cells (this work)
• CHO α2A-S347amb-SNAP (Capricorni) cells (this work)
• CHO α2A-S360amb-SNAP (Deneb) cells (this work)
• CHO α2A-K370amb-SNAP (Enif) cells (this work)
• CHO α2A-T373amb-SNAP (Fafnir) cells (this work)
• E. coli (TOP10) (#C404010 Thermo Fisher Scientific)
3.1.2. Cell Culture Media and Supplements
• Dulbecco’s modifies Eagle’s medium (DMEM)/F-12 without phenol red (#11039-
021 Gibco)
• Dulbecco’s modifies Eagle’s medium (DMEM) with phenol red (#21969-035 Gibco)
• Dulbecco’s phosphate buffered saline (DPBS) without Ca2+ and Mg2+ (#14190-
094 Gibco)
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• Reduced serum medium (Opti-MEM) (#11058-021 Gibco)
• Fetal bovine serum (FBS) (#S0115 Biochrom AG)
• Penicillin/Streptomycin (#P4333 Sigma-Aldrich)
• Trypsin/EDTA solution (#P10-023100 PAN Biotech)
• L-Glutamin (#P04-80100 PAN Biotech)
3.1.3. Dyes
• SNAP-Cell 430 (#S9109S New England BioLabs (NEB))
• SNAP-Surface 488 (#S9124S New England BioLabs (NEB))
• SNAP-Cell 505-Star (#S9103S New England BioLabs (NEB))
• SNAP-Cell TMR-Star (#S9105S New England BioLabs (NEB))
• SNAP-Surface Alexa Fluor 546 (#S9132S New England BioLabs (NEB))
• SNAP-Surface 549 (#S9112S New England BioLabs (NEB))
• SNAP-Surface Alexa Fluor 647 (#S9136S New England BioLabs (NEB))
• SNAP-Cell 647-SiR (#S9102S New England BioLabs (NEB))
• SNAP-Surface 649 (#S9159S New England BioLabs (NEB))
• CLIP-Surface 488 (#S9232S New England BioLabs (NEB))
• CLIP-Cell 505 (#S9217S New England BioLabs (NEB))
• CLIP-Cell TMR-Star (#S9219S New England BioLabs (NEB))
• CLIP-Surface 547 (#S9233S New England BioLabs (NEB))
• CLIP-Surface 647 (#S9234S New England BioLabs (NEB))
3.1.4. Plasmids
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3.1.5. Laboratory Equipment and Accessories
Adhesion microscope slides SuperFrost Plus R©, R. Langenbrinck
Attofluor cell chamber Thermo Fisher Scientific
Agarose gel system Agaget Standard, Whatman Biometra
Bio-Rad Gene Pulser II #165-2077, Bio-Rad
Blotting chamber Criterion Blotter, BioRad
Centrifuge EBA 12R Hettich
Centrifuge Rotanta 96R Hettich
Centrifuge 5810R Eppendorf
Electrophoresis Power Supply EPS 301, Amersham Biosciences
Electrophoresis Unit SE600 Series, Hoefer
Electroporation cuvettes #165-2088, BioRad
Glass fiber filters without binders #APFF02500, Merck
Inverted Laboratory Microscope Leica DM IL
Liquid Scintillation Analyzer Tri-Carb R© 2910 TR Perkin Elmer
Microscope cover glasses 24 mm #0111640, Marienfeld superior
NanoDrop 2000 C Spectrophotometer Thermo Fisher Scientific
Scintillation Vials 20 ml #SZFL, Hartenstein
Shaker Heidolph Reax 2000
Sonicator Tip Sonopuls HD206, Bandelin
Ultracentrifuge LE-70 Beckman
Ultraturrax T8, IKA Labortechnik
3.1.6. Chemicals and Reagents
Rotiszint R© eco plus LSC Universalcocktail #0016.3 Roth
Lipofectamine R© 2000 #11668019 Thermo Fisher Scientific
Effectene Transfection Reagent #301427 QIAGEN
jetPRIME R© #114-01 VWRTM
30
3.1. Materials
3.1.7. Antibodies
Primary antibodies
• Mouse monoclonal anti-HA-tag (# 901513 Biolegend)
• Rabbit polyclonal anti-SNAP-tag (#CAB4255 Thermo Fisher)
Secondary antibodies
• Goat anti-mouse horseradish peroxidase conjugate (#115-035-003 Jackson Im-
munoResearch)
• Goat anti-rabbit horseradish peroxidase conjugate (#111-035-144 Jackson Im-
munoResearch)
3.1.8. Solutions
2x BBS
• 280 mM NaCl
• 1.5 mM Na2HPO4
• 50 mM BES
FRET buffer
• 5 mM KCl
• 137 mM NaCl
• 1 mM MgCl2
• 2 mM CaCl2
• 10 mM HEPES
• pH 7.3
smFRET buffer
• 10 mM Tris at pH 8.0
• 50 mM NaCl
• 1 %/v D-glucose
• 25 U/ml glucose oxidase1
• 250 U/ml catalase1
1GOCAT already as stock prepared, needs to be diluted 50 fold
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• 1 mM chloramphenicol
• 1− 2 mM Trolox
10% separation gel
Recipe for two gel 14 loading chambers
• 7.2ml Rotiphorese 30
• 5.6ml 1.5 M Tris, 0.4% SDS
• 9.75ml H2O
• 300µl 10% APS
• 22.5µl Temed
Running buffer
• 25 mM Tris
• 190 mM glycine
• 1% SDS
• pH 8.3
TBS-T
• 10 mM Tris pH 7.4
• 100 mM NaCl
• 0.1% Tween20
Transfer buffer
• 25 mM Tris
• 150 mM glycine
• 10% methanol
Washing buffer
• 50 mM Tris pH 7.4
• 150 mM NaCl
• 0.2% BSA
• 0.2% NP-40
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RIPA buffer
• 50 mM Tris pH 7.2
• 150 mM NaCl
• 1% NP40
• 0.5% sodium deoxycholate
• 0.1% SDS
Lysis Buffer GTPγS
• 5 mM Tris
• 2 mM EDTA
• pH 7.4
Binding buffer
• 20 mM HEPES
• 10 mM NaCl
• 10 mM MgCl2
• pH 7.4
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3.2. Methods
3.2.1. Transformation (Top 10)
For the amplification of plasmids, chemically competent E. coli (TOP10) were used.
20µl 5× KCM buffer, 80µl ddH2O and 0.75µg of plasmid DNA were mixed in a 1.5ml
Eppendorf tube. After addition of 100µl of competent cells the mixture was incubated
for 20 minutes on ice followed by 10 minutes incubation at room temperature. Then
1ml Luria Bertani (LB) medium was added followed by 50 minutes incubation at 37◦C
with horizontal shaking. From this mixture 100µl were taken and plated on agar plates
by spreading with a sterilised instrument. The agar plates contained the appropriate
antibiotic, namely either ampicillin at a final concentration of 0.1mg/ml or kanamycin
at a final concentration of 0.04mg/ml. The agar plates were incubated overnight for
14-16 hours at 37◦C to obtain isolated colonies. The following day, a single colony was
picked and used for the plasmid amplification (3.2.2).
3.2.2. Plasmid amplification
For plasmid DNA extraction and purification the Qiagen MIDI plus kit was used fol-
lowing the manufacturer’s protocol with modifications. Either a single colony from the
transformation from the previous day (section 3.2.1) or a swab from a gylcerol stock
of transformed bacteria was used to inoculate in 2ml LB medium supplemented with
the appropriate antibiotic. This mixture was incubated for 8h at 37◦C with horizontal
circular shaking at 180 rpm. Then, 50µl of this culture were taken to inoculate 50ml
LB medium supplemented with either 50µl ampicillin or kanamycin. %TODO After
incubating this culture overnight for 14-16 h at 37◦C with horizontal circular shaking
at 180 rpm, the culture was centrifuged at 4◦C with 4000 rpm for 15 minutes. The
so obtained bacterial pellet was resuspended and homogenised with a pipette in 4ml
resuspension buffer P1 containing LyseBlue. Then, 4ml of lysis buffer P2 were added
and the mixture was gently mixed by inverting it 4 to 6 times and incubated at room
temperature (RT) for 3 minutes. After this incubation, 4ml neutralisation buffer S3
were added and the mixture was gently mixed again by inverting it until all traces of
blue were eliminated. The lysate was then centrifuged at 4000 rpm at RT for 5 minutes
before it was transferred into a QIAfilter cartridge. The lysate was incubated 5 minutes
followed by a filtration into a 15ml tube and an addition of 2ml binding buffer BB.
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The mixture was gently mixed by inverting the tube 4 to 6 times and then transferred
to a vacuum pump assembly where the lysate ran through a column. The column was
washed by adding 700µl wash buffer PE and centrifugation with 10000 ×g for 1 minute
at RT. Next, 700µl buffer ETR with ethanol were added followed by another 1 minute of
centrifugation. To remove any buffer traces, the column was centrifuged again before the
DNA was eluted. Afterwards, 100µl ddH2O were added on the column, incubated for 5
minutes at RT and then the DNA was collected in a sterile 1.5ml tube by centrifugation
with 10000 × g for 1 minute at RT. A NanoDrop 2000 (from Thermo Fisher Scientific)
was used to measure the DNA concentration and purity. The DNA concentration was
adjusted to 1µg/µl and the aliquot stored at −20◦C.
3.2.3. Cloning
The insertion of unAA into our receptor of interest (α2A-AR) was performed by substi-
tuting amino acids in the third ICL. Serine and Lysine have been shown to be the most
promising amino acids for the replacement with an unAA (Beliu et al. unpublished). 5
target amino acids were chosen: 2 Lysine, 2 Serine and 1 Threonine. The mutagenesis
was performed on α2A-AR-wt. As an example, the cloning scheme for the K327amb
mutant is described. First, two single cutting sites were chosen around the insertion side
chain. In this case BspEI downstream and XbaI upstream and the respective primers
were designed. A second set of primers was designed with the same sequence as the
original receptor around the insertion side chain with a length of 30 bases. For the
reverse primer the codon for lysine was replaced by ’ATC’, which is the amber codon.
Accordingly, the forward primer contained ’TAG’ at the respective site. A polymerase
chain reaction (PCR) was run with the forward primer containing BspEI and the reverse
primer with the amber mutation. A second PCR was used for the forward primer with
the amber mutation and the reverse primer containing XbaI. The products of those two
PCRs were used as templates for a third PCR, giving a product that was then ready
to be inserted via the two single cutting sites into the α2A-AR-CLIP-SNAP. The final
product contained a substitution with an amber codon in the third ICL and a SNAP-tag
at the C-tail. The PCRs were performed by Dr. Ulrike Zabel (Institute of Pharmacology,
University of Wu¨rzburg).
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3.2.4. Preparation of superclean coverslips
Glass coverslips with a diameter of 24mm were placed in a custom made holder, which
was then placed into a beaker. The coverslips were covered with chloroform and the
beaker was sealed with aluminium foil. The beaker containing chloroform and coverslips
was sonificated for 30 minutes. Afterwards, the holder was taken out and left to dry
before it was placed in a beaker containing 5M NaOH, covered with aluminium foil and
sonificated for 30 minutes. Next, the coverslips were washed 3 times with super-pure
water before being stored in 99.98 % ethanol.
3.2.5. Cell culture
CHO cells
chinese hamster ovary (CHO) cells were cultured in 10 cm petri dishes in complete
culture medium (DMEM/F-12 supplemented with 10V% fetal bovine serum (FBS),
100U/ml penicillin and 100µg/ml streptomycin) at 37◦C and 5% CO2. The cells were
routinely passaged at a confluence of 70 − 90%. The cells were washed gently with
phosphate-buffered saline (PBS) and detached by an incubation of 2 minutes with 1ml
Trypsin/EDTA. Trypsin was then inhibited with complete medium and the cells were
detached, homogenised and collected. A fraction of the cell suspension was then cultured
in a new plate containing fresh medium.
The stable clones derived from CHO cells were cultured with the same conditions, with
the addition of 500nm/µl gentamicin.
HEK293 A cells
HEK293 A cells were cultured in complete culture medium (phenol red-free DMEM
supplemented with 10V% FBS, 2mM L-Glutamine, 100U/ml penicillin and 100µg/ml
streptomycin) at 37◦C and 5% CO2. The cells were routinely passaged at a confluence
of 70− 90%. The cells were washed gently with PBS and detached by an incubation of
2 minutes with 1ml Trypsin/EDTA. Trypsin was then inhibited with complete medium
and the cells were detached, homogenised and collected. A fraction of the cell suspension
was then cultured in a new plate containing fresh medium.
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3.2.6. Creation of stable cell lines
For the generation of stable cell lines (3.1.1), CHO cells were seeded the evening before
transfection at a density of 1 × 106 cells per 10 cm Petri dish to achieve a confluence
of 70 − 80%. On the next morning, the cells were transfected via Lipofectamine R©
2000 (refLipo) with 12µg plasmid DNA and 36µl Lipofectamine R© 2000. In parallel a
control plate was transfected with the empty expression vector (pcDNA). After 24h, the
medium was replaced with fresh medium containing the selection antibiotic, in this cases
gentamicin (G418) at a final concentration of 500ng/ml. The following day, the cells
were split and after 4-6 hours the selection antibiotic was added to the transfected stable
cell line as well to the control plate again. After a few days all cells of the control plate
died. Depending on the transfection efficiency also 5− 10% of cells from the transfected
plates died. The surviving cells, which contained the resistance, were routinely passaged
using the medium containing the selection antibiotic. This selection pressure of the
antibiotic was kept for 2-3 weeks, until the new cell line could be considered ’stable’.
Then, aliquots were frozen and stored. For the purpose of some experiments the stable
cells were diluted and plated in a 96-well plate in order to obtain single clones. The wells
were checked each day and those containing more than one cell were not considered. The
single clones were then cultured and checked for expression level by fluorescent labelling
and TIRF microscopy, before aliquots of them got frozen and stored.
3.2.7. Transfection
Via Lipofectamine R© 2000
The evening before the transfection, CHO cells were seeded on 24mm superclean cov-
erslips (3.2.4) at a density of 170, 000 cells per well of a 6-well plate. The next morning,
for each well, 0.5ml of Opti-MEM medium was incubated with 2µg of plasmid DNA
and in parallel 0.5ml of Opti-MEM medium was incubated with 3µl of Lipofectamine R©
2000. After 5 minutes of incubation, the mixtures were pooled and incubated for 20
minutes at room temperature.
Before the transfection, cells were washed once with PBS and then with 1ml of DMEM/F-
12 medium supplemented with FBS was added. After the 20 minutes incubation 1ml
of the transfection mixture was added dropwise in a spiral manner on top of the cells.
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Via electroporation
Confluent plates of CHO cells were trypsinised, centrifuged and adjusted to a concentra-
tion of 5×106 cells/ml. For the transfection, 400µl cell solution, 20µg plasmid DNA and
0.5µl dye (each) were added to a 4mm cuvette. The cuvette was put into the Bio-Rad
Gene Pulser II to electroporate with 0.25V and 960µFD. After the shock, 800µl of
pre-warmed medium were added slowly and gently and then left for 20 minutes. Before
seeding on coverslips, the cell solution was centrifuged for 5min at 850 rpm and the
supernatant was replaced with fresh medium.
Via Effectene
The evening before transfection, HEK 293 AD cells were seeded with a density of 200, 000
on clean 24mm coverslips. Just before the transfection, the cells were washed with
PBS and then 2ml of fresh phenol red-free medium was added. Per 6-well 1µg of
plasmid DNA was added to 150µl ECL-buffer, incubated for 2 minutes and followed
by the addition of 4µl of Enhancer and another 2 − 5 minutes of incubation. Then,
12.5µl of Effectene were added, the whole mixture was incubated for 20 minutes at
room temperature and 150µl of the mixture was added dropwise in a spiral manner.
Via calcium chloride
HEK293 AD cells were seeded in the morning in 10 cm plates to reach a confluence of
70% 4 hours later. Then, the cells were transfected. Therefore, a mixture of 450µl
sterile H2O, 10µl plasmid DNA, 50µl of CaCl2 2.5M and 500µl 2× BBS were mixed
for the transfection of one 10 cm plate. The solution was mixed vigorously before it
was incubated for 30 minutes at room temperature. 950µl of the mixture were added
dropwise to the plate and the cells were incubated for 48 hours.
Via Jet-Prime
CHO cells were seeded the evening before at a density of 80, 000 cells in 6-well plates.
The next morning, the following transfection mixture was prepared. First, per well of
a 6-well plate, 1µg of plasmid DNA was added to 100µl of Jet-Prime buffer and the
mixture was vortexed. Next, 2µl of Jet-Prime reagent were added, the solution was vor-
texed again and incubated for 10min at room temperature before it was added slowly
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and dropwise to the cells. [106]
If the plasmid coding for the tRNA/synthetase for the incorporation of an unnatural
amino acid was transfected, a second mixture was prepared additionally. For this pur-
pose, 2.5µl of 100mM trans-Cyclooctene (TCO) was mixed with 7.5µl of 1M HEPES
buffer. This mixture was added very slowly on the edge to minimize stress for the cells.
[106]
3.2.8. Preparation of supported membranes
The preparation of supported membranes was performed following the protocol from
Perez et al. ([113]). CHO cells were seeded at a density of 250, 000 cells on Poly-
L-Lysine (PLL) coated superclean glass coverslips with a diameter of 24mm. Glass
slides were coated with PLL just before the experiment. A coverslip was taken and
the remaining medium was removed by touching the edge of the coverslip on a paper
tissue. The coverslip was turned with the cells facing the object plate and placed on
the glass slide with a small part of the coverslip standing over the edge of the object
plate as illustrated in figure 3.1. The thus assembled ”sandwich” was turned upside
down and pressed on a paper tissue. Manual pressure was applied directly above the
coverslip and on its sides (area 1 and 2 shown in figure 3.1). This assembly was left at
room temperature for about one minute. The coverslip was then released by pushing
the overlapping edge with a tweezers and pulling up the object plate gently to avoid
breaking it. The coverslip was placed with the cell side up again in medium and was
gently washed two times with PBS before proceeding with labelling.
3.2.9. Labelling
Via SNAP- and CLIP-tag
Transfected cells or membranes containing a SNAP- and/or a CLIP-tag were labelled
accordingly before imaging. First, the cells were washed with PBS. Then the dye was
solubilised in culture medium with a final concentration of 1µM . The samples were
incubated with the labelling solution for 20 minutes at 37◦C. Afterwards, the cells
were washed twice with fresh medium and incubated for 5 minutes. This washing was
repeated three times before imaging of the cells.
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12 2
a
b
c
Figure 3.1.: Illustration of supported membrane preparation. a) red zones 1 and 2 show where
to apply pressure; b) the green area indicates how to release the coverslip again
Via click chemistry
Click labelling was performed according to the protocol of Nikic´ et al.. [106] For this
reason, tetramethylrhodamine (TAMRA) was diluted in complete medium. The freshly
prepared mixture was added and the cells were incubated for 10 minutes at 37◦C.
Afterwards, the coverslip was washed once with fresh medium and mounted directly in
a microscopic chamber with 400µl medium. The protocol was later changed to three
additional washing steps with 5 minutes incubation in-between, to reduce unspecific
labelling.
3.2.10. Single-molecule TIRF microscopy
After labelling, the coverslip was mounted into an imaging chamber and 400µl of medium
were added. Imaging was performed on a customised Nikon Eclipse Ti TIRF microscope.
For the excitation a 561nm and a 638nm diode laser by Coherent were used, along with
a quadruple band filter. If not stated otherwise, the imaging chamber was mounted on
a 100× oil-immersion objective (CFI Apo TIRF 100×, NA 1.49) and the fluorescence
emission was detected by EMCCD cameras (iXon DU897, Andor). The objective was
kept at 20◦C via a water-cooling system (Julabo). Movies were acquired using NIS-
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Elements AR imaging software (Nikon). The powers of the lasers were adjusted according
to the type of experiment. The images were cropped to 448 × 448 pixels and acquired
in frame transfer, resulting in a frame rate of 35 frames per second.
Binding curves of fluorescent ligands
CHO cells were transfected via Lipofectamine R© 2000 for 24 hours with the respective
wild-type receptor. For labelling, the fluorescent ligand was diluted in culture medium,
spanning several logs of concentration to obtain a full binding curve. The cells were
incubated with the ligand solution for 20 minutes and then mounted into an imaging
chamber with fresh medium. Imaging was performed at 20◦C using a 60× objective of
a TIRF microscope. That way, several cells could be imaged within one frame. Pictures
or short movies of at least 60 cells were obtained for each ligand concentration.
For each binding curve, negative controls were performed, either transfection of the
empty expression vector or transfection of a different subtype of the receptor family, to
check for unspecific binding.
Wash resistance test
CHO cells were transfected via Lipofectamine R© 2000 for 24 hours with the respective
wild-type receptor. The fluorescent ligand was diluted in culture medium. The cells
were washed with PBS before being incubated for 20 minutes, with a concentration of
ligand ≈ 100 × kD value, and then mounted into the imaging chamber with 400µl of
medium. Imaging was performed using a 60× objective at a TIRF microscope. A frame
with several labelled cells was recorded with a laser power of 15%. The cells were then
carefully washed once with medium while mounted at the microscope. At this step care
was taken to avoid touching of the chamber and coverslip. After washing, the focus
was adjusted again on the cells using low laser intensity (2-3%) and then one frame was
recorded every minute at 15% laser power.
As a bleaching control a movie was obtained without washing using the same laser power
(15%).
3.2.11. Single-molecule FRET experiments
After the preparation of supported membranes (section 3.2.8), the cells were washed once
with PBS and then treated for 30 minutes with apyrase to degrade all nucleotides. Next,
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the supported membranes were labelled with the fluorescent dyes, as described above.
To prevent bleaching and blinking in the smFRET experiments, an oxygen scavenging
system was used. The smFRET buffer was prepared fresh by addition of glucose oxidase
and catalase to a final concentration of 25U/ml and 250U/ml respectively. From this
mixture, 200µl were added in the centre of an object plate. The coverslip with the
labelled supported membranes was inverted and shortly touched on the edge of a tissue
paper to get rid of surplus medium. Then, by approaching with the coverslip to the
drop of smFRET buffer, the buffer spread below the coverslip, and the coverslip was
centred on the glass slide. The excess of buffer was removed by shortly touching with
a paper tissue on the edge of the ”sandwich”. Last, nail polish was used to seal the
sample (preferably fast drying nail polish). In this way, the probe was shielded from
new oxygen entering and the oxygen scavaging system could work effectively. When the
nail polish dried, imaging started immediately.
The imaging was performed with the same Nikon TIRF set-up as described above. A
laser power of 15% was used for SNAP549 and CLIP647 each. Supported membranes
with a single-molecule level were searched for using the 639nm laser, with the laser
power at 3% to minimize photo bleaching. If a cell patch was found, first a movie was
recorded, imaging both acceptor and donor channel simultaneously, while exciting the
donor, SNAP 549. Second, a control movie of the acceptor excitation was acquired.
When apyrase treatment was performed, nucleotides (GTP, GTPγS or GDP) or ligands
(Noradrenalin or Yohimbine) were added to the smFRET buffer.
3.2.12. Ensemble FRET
HEK293 AD cells were seeded on PLL coated clean glass coverslips with a diameter
of 24mm. After a transfection via effectene for 48 hours, the cells were prepared for
imaging. If they contained SNAP- and CLIP-tags, they were labelled accordingly. Before
imaging, the cells were washed with PBS and then fresh complete medium was added.
The coverslip was mounted in an imaging chamber and washed 3 times with FRET
buffer. The such prepared sample was mounted on the FRET set-up described at section
6.1.2, after a drop of immersion oil was dispensed on the objective. The cells were focused
using dim bright light. Long flashes of the excitation wavelength were used to search
cells with a high expression level on the membrane, which were then centred on the
assembled screen. The perfusion tip was carefully placed, so that the flow was not wash
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away the cell before the measurement was started using an excitation of 10/100ms.
During the experiment, different solutions were perfused to the cell using the perfusion
system controlled by a key board.
At the end of each measurement, a bleed through control was added by switching to the
excitation wavelength and filter set for the acceptor.
3.2.13. GTPγS assay
Cells were cultured in 10-cm plates and co-transfected via calcium chloride with plasmids
for the receptor of interest, Gi, Gβ and Gγ. As a negative control, additional plates were
transfected with the empty expression vector using pcDNA. As a positive control, the
wild-type receptor was also transfected with the G-proteins. In addition, a general
control to estimate the transfection efficiency for the calcium transfection, one plate was
transfected with EYFP, which was checked after 48 hours at a fluorescence microscope.
If the transfection efficiency was above 30-40%, cells were put on ice and lysed by adding
5ml lysate buffer per plate. The cells were collected with the help of a rubber policeman
and collected in a Falcon tube, where they were homogenised using a blade homogeniser
(Ultra Turrax). The lysates were centrifuged for 3 minutes at 850 rpm and 4◦C. The
supernatant was centrifuged again with a ultracentrifuge for 40 minutes at 37, 000 rpm
and 4◦C. The pellet was solubilised in 1ml binding buffer and grinded 5 to 10 times
using a glass potter. The protein quantification was performed using the Biorad protein
assay.
Each transfection was divided into 3 groups: one unstimulated, one with 100µM GTP
and one stimulated with 100µM norepinephrin (NE). For each group, triplicates for 6
different reaction times were measured: 0 s, 15 s, 30 s, 60 s, 120 s and 300 s, resulting in
18 samples per group. For each sample 10µg of membranes were used and GTPγS with
an average radioactivity of 120, 000 cpm. This amount corresponds to 0.0545µCi giving
the relation:
2.2 × 106 cpm =̂ 1µCi (3.1)
Glass fibre prefilters were soaked in MilliQ water. The calculated amount of radioac-
tive GTPγS was solubilised in binding buffer. The sample tubes were filled with binding
buffer beforehand. The reaction was started in a separate tube by adding the GTPγS
and mixing. At the respective time points, samples were taken and put on ice to stop
the reaction. Afterwards, the samples were transferred onto a pump assembly to run
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through the filters. The filters were then washed 3 times with binding buffer before they
were put into scintillation tubes. The tubes were filled with 8ml of scintillation oil and
the radioactive samples were measured in a liquid scintillation analyzer (Tri-Carb R© 2910
TR Perkin Elmer) each for 5 minutes.
3.2.14. Lysis
Confluent plates of the transfected cells were taken and incubated for 10 minutes with
1ml of fresh RIPA buffer. Then, the cells were scraped and the lysate was filled into an
Eppendorf tube. After three pulses of sonification, each of 15 seconds, the lysate was
centrifuged for 30 minutes at 10, 000 rpm at 4◦C.
3.2.15. Western blotting
For western blotting, 10 % SDS gels were mounted in an electrophoresis chamber filled
with running buffer. Before loading, the samples were mixed with 5× Laemli buffer.
The electrophoresis was started at 80V for 20 minutes, and then increased to 150V and
run until the blue Laemli reached the lower end of the gel. The PVDF membrane was
activated for blotting by an incubation in methanol for 10 minutes. While building the
blotting casette, care was taken to have the correct order and orientation of gel, PVDF
membrane and electric poles.
The assembled blotting cassette was mounted in the blotting chamber filled with
transfer buffer, and an additional cooling akku. Blotting was done at 100V at 4◦C for
50 minutes. Next, the membrane was blocked for 1 hour in 2.5% dry milk followed by an
incubation overnight with the primary antibody. The following morning , the membrane
was washed three times for 10 minutes each with washing buffer. Then it was incubated
for 1 hour with the secondary antibody and again washed 3 times for 10 minutes each
with washing buffer. A luminol mixture was prepared and spread on the membrane
incubating for 1 minute. Finally, the membrane was developed.
3.2.16. Data processing
Single-molecule movies
Movies from single-molecule experiments were sorted for low expressions levels, good
focus and high signal-to-noise ratio. The thus selected movies were prepared for the
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automated particle detection and tracking in Matlab. Therefore, a mask was drawn in
Fiji is just ImageJ (FIJI) around the cell or membrane patch that should be tracked.
The movies were then analysed with customised scripts, based on the tracking algo-
rithm developed by Jaqaman et al. [75]. If further analysis was performed, this will be
described in the corresponding results section.
Ensemble FRET
The data from ensemble FRET experiments was analysed in Origin (from OriginLab
Corporation). For each measurement the direct excitation peak for the acceptor was
taken to correct the overall measurement for bleed through and false direct excitation
by calculating:
FtrueAcc = FAcc − FDon · b− d · EAcc (3.2)
Where FtrueAcc is the corrected acceptor fluorescence emission, FAcc is the measured
fluorescence acceptor emission, FDon is the measured donor fluorescence emission, b is
the bleed through correction factor, d the direct excitation correction factor and EAcc
the fluorescence emission measured for the acceptor control in each experiment.
The correction factors were determined previously for the FRET set-up. For the FRET
ratio, the acceptor emission is divided by the donor emission. The ratio was then nor-
malised and plotted over time. The changes according to stimulation could be deter-
mined directly.
Binding curves
To obtain the mean intensity for each cell, a mask of the cell shape was created in FIJI.
The background intensity was subtracted. At least 50 cells per condition from three
independent experiments were taken. Per concentration, all cells were averaged and the
standard error of the mean (SEM) was calculated. Intensity values were normalized to
those obtained with the highest concentration (10µM). Data were fitted to a one site
ligand binding model with Hill slope of 1 in Prism 6 (GraphPad Software Inc.).
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Washout curves
The acquired image sequences of the washout experiments were analysed using FIJI. A
region of interest (ROI) was manually defined for each cell and its background-subtracted
average intensity was measured. The intensity values were normalised to the starting
intensity. Data were plotted and fitted to a one-phase exponential decay in Prism 6. The
curve for Cy5 was corrected for bleaching as it showed 21 % photo bleaching in 20 frames.
For this reason the intensities from the bleaching control movie were fitted linearly in
Origin, and the values were added to the measured intensities of the washout experiment.
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4. Results
As mentioned above (section 1.6.3), fluorescent ligands can be used to label and inves-
tigate GPCRs. A set of fluorescent ligands was generated by Prof. Michael Decker’s
group. Two sub-type selective MOR ligands, containing 14β-(p-nitro-cinnamoylamino)-
7,8-dihydrocodeinone (CACO), were synthesised by Christian Gentzsch and a pair of
fluorescent ligands for DOR was synthesised by Antonios Drakopoulos, based on the
antagonist naltrindole. The respective structures are shown in 4.1.
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Figure 4.1.: The structures of the synthesised fluorescent ligands. A and B compounds from
Christian Gentzsch for µOR. Both have as parent compound CACO. A tetraglycin
functions as linker to A) a Cy3 and B) a Cy5. C and D compounds from Antonios
Drakopoulos for δOR. Both have as parent compound naltrindole. A tetraglycin
functions as linker to C) a Cy3 and D) a Cy5.
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4.1. Investigating the binding affinity of the new ligands
The compounds provided by Prof. Decker’s group all showed a good selectivity and high
signal-to-noise ratio in first tests. This made them applicable for investigations using
fluorescent microscopy techniques. A crucial question, when applying changes to the
structure of a ligand, is whether or in which regards the structural changes translate
into pharmacological changes. Hence I performed binding experiments to determine the
affinity of the ligands.
CHO cells were transiently transfected with wild-type MOR or DOR for 24 h and
afterwards incubated for 20 min each with 8 different concentrations of the fluorescent
compounds. The concentrations were chosen to cover a range that would allow to reach
a plateau for low binding and a saturation plateau for 100 % binding. For each concen-
tration at least 40 cells were measured. Three individual experiments were acquired for
each compound, each normalised to the highest concentration, and all three thus ob-
tained binding curves were averaged and fitted with a logarithmic dose response curve
in Prism. The results are shown in figure 4.2. The fitting gave a kD of 87.29± 49 nM for
Caco-Gly4-Cy3 and of 295.2± 141 nM for the Cy5 variant with R2 = 0.8573 and 0.9149
respectively.
The same analysis was performed for the compounds for the DOR giving kD = 2.265±
0.753 nM and kD = 5.673 ± 1.931 nM for Anti-Delta-Cy3 and Anti-Delta-Cy5 respec-
tively with R2 of 0.9595 and 0.9644.
Thus, the attachment of the fluorophores via a linker indeed leads to changes in the
pharmacological properties compared to the parent compounds.
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Figure 4.2.: Binding curves of the fluorescent ligands. A) shows the compounds for the µOR,
the Cy3 variant in green, Cy5 in magenta. B) are the binding curves for the
δOR compounds, Cy3 again in green and Cy5 in magenta. All curves are fitted
with a sigmoidal curve and the SEM are shown for all concentrations. The mean
represents three independent binding experiments for all curves.
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4.2. Do the ligands possess wash resistance?
As the parent compounds were reported to show some wash resistance, I wanted to
assess how the chemical modifications changed this property. The experiments were
performed with transiently transfected CHO cells. One picture was taken before the
cells were washed while mounted on the microscope and then another picture was taken
once every minute. As a control for bleaching a movie of 20 frames was obtained using
the same laser power. In case of Caco-Gly4-Cy5, the wash-out curve was corrected for
the bleaching derived from the control movie, as it contributed significantly. The average
intensity of the same cells was normalised to the initial intensity and fitted with a one-
exponential decay in Prism as shown in figure 4.3. It was observed that the compounds
wash out fast in the first few minutes and then slow down reaching a plateau. The loss
of fluorescence intensity can be seen already by eye in panel A of figure 4.3, showing the
same cells over the course of 12 minutes. In the case of Caco-Gly4-Cy3, 34± 4 % of the
ligand stays bound (R2 = 0.9932) and for Caco-Gly4-Cy5 54± 3 % (R2 = 0.9805).
From the two compounds for DOR the ligand linked to Cy3 was tested for wash resis-
tance in this work. Anti-Delta-Cy3 reaches a plateau at 69± 3 % with a R2 = 0.9884 as
shown in figure 4.4. The Cy5 variant was measured by the collaboration partner Anto-
nios Drakopoulos and he could obtain a wash resistance of 93 ± 1 % with R2 = 0.8095
(data not shown).
This proves that the chemical modifications also lead to changes in the wash resistance,
while still preserving the overall property. Interestingly in both cases the compound
containing Cy5 shows a significant higher wash resistance than the compounds with Cy3.
4.3. Single-Molecule experiments to unravel the
diffusion behaviour
Since all the different compounds showed a good signal-to-noise ratio and suitable pho-
tophysical properties, I applied and used them for single-molecule imaging. Transiently
transfected CHO cells with wild-type MOR or DOR, respectively with an average re-
ceptor density of approximately 0.85 receptors/µm2 for MOR and 1.18 receptors/µm2
for DOR were used. Thus, the expression level was low enough to perform automated
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Figure 4.3.: Wash resistance of the µ OR ligands. A) shows labelled cells after one wash.
The decrease of fluorescence intensity was clearly observable by eye. B), washout
curves. The values are fitted to a one exponential decay showing that both com-
pounds reach a plateau. The plateau for the Cy3 compound (shown in green)
is 34 % whereas Caco-Gly4-Cy5 (magenta) reaches a plateau at 54 %. Points are
averaged over 12 cells out of 4 individual experiments, shown with SEMs.
particle detection and tracking. The scripts used in our lab are based on the algorithm
presented by Jaqaman et al. in [75] and customised for our purposes. After tracking,
the obtained trajectories were analysed for the time-averaged mean squared displace-
ment (TAMSD), allowing to categorise the particles into the different classes of motion.
In the case of MOR, the cells were incubated with Caco-Gly4-Cy3. Even though the
compound showed less wash resistance, Cy3 is more photostable allowing longer obser-
vations of individual particles. Due to wash-out of the ligand over time (the compound
possesses a wash resistance of only 34 %), the cells were just imaged in the first 4−5 min
after mounting in the imaging chamber. The analysis revealed that 22 % of MOR are
virtually immobile, 34 % show sub-diffusive behaviour, another 34 % diffuse normally
and 10 % show super-diffusion.
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Figure 4.4.: Wash resistance of the δ OR ligand with Cy3. The values are fitted to a one
exponential decay showing that the compounds reaches a plateau of wash resistance
at 69 %. Points are averaged over 12 cells out of 4 individual experiments, shown
with SEMs.
The fluorescent ligands for DOR exhibits a higher wash resistance, nevertheless the
samples were not imaged longer than 10 min. Else, the number of trajectories that are
prematurely ended by ligand dissociation or bleaching would be to high. Again, the
variant with Cy3 was chosen for the same reasons mentioned above. The DOR shows
heterogeneous diffusion behaviour as well, with 27 % being virtually immobile, 38 % be-
ing sub-diffusive, 27 % normally diffusing and 9 % of receptors being super-diffusive.
The novel fluorescent ligands were successfully applied to investigate the diffusion of
the two subtypes on a single-molecule level. In both cases, the diffusion behaviour is
heterogeneous but similar amongst the subtypes.
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Figure 4.5.: Time-averaged mean squared displacement analysis for µOR. A) shows example
trajectories and the corresponding TAMSD curves for the four categories of dif-
fusive behaviour. B) shows the fractions of all four categories. 2225 individual
particle trajectories were analysed from 29 different cells.
55
4. Results
A
10 µm
Immobile
Time/s
TA
M
SD
/µ
m
2
0 0.5 1
2
1
0
Sub-diﬀusion
0 0.5 1
2
1
0
Time/s
TA
M
SD
/µ
m
2
Normal diﬀusion
0 0.5 1
2
1
0
Time/s
TA
M
SD
/µ
m
2
0 0.5 1
2
1
0
Super-diﬀusion
Time/s
TA
M
SD
/µ
m
2
2µm 2µm
2µm 2µm
Im
mo
bil
e
Su
b-d
iﬀus
ion
No
rm
al 
diﬀu
sio
n
Su
pe
r-d
iﬀus
ion
Fr
ac
tio
n
0.0
0.1
0.2
0.3
0.4
0.5B
Figure 4.6.: Time-averaged mean squared displacement analysis for δOR. A) shows example
trajectories for the four categories of diffusive behaviour and the corresponding
TAMSD curves. B) shows the fractions of all four categories. The TAMSD was
calculated from over 1103 individual trajectories taken from 31 different cells.
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4.4. Investigation of dimerisation
To look at possible homodimers of µ opioid receptors, CHO cells were transiently trans-
fected with the wild-type receptor and after 5− 6 h labelled with a mixture of both flu-
orescent MOR ligands, Caco-Gly4-Cy3 and Caco-Gly4-Cy5. To achieve roughly similar
labelling for both colours, the concentrations were adjusted to 1µM for Caco-Gly4-Cy3
and 0.5µM for Caco-Gly4-Cy5. The detected density for the Cy3 channel was on average
0.9 ± 0.08 receptors per µm2 and for Cy5 0.8 ± 0.05 receptors per µm2. As for the one
colour experiment, care was taken to only image within the first minutes after mounting,
to reduce the effect of wash-out. TIRF imaging movies were acquired simultaneously in
both emitting channels.
The thus acquired movies were analysed using automated particle detection and track-
ing. After tracking, of both channels individually, further analysis was employed to check
for colocalisation using a customised Matlab script. The colocalisation and all following
analysis were performed in collaboration with Dr. Yann Lanoisele´e (AG Calebiro, Insti-
tute of Metabolism and Systems Research, University of Birmingham). Both channels
were aligned correctly using images of fluorescent beads, which were imaged before each
experiment, allowing corrections of possible distortions or translations later on. The re-
sult of the colocalisation script is an interaction matrix for all colocalisations, as there is
no possibility to distinguish between random colocalisation or ’real’ colocalisation due to
protein-protein interaction. In mathematical terms the true interactions are convolved
with random colocalisations, and the end result is a mixture containing all colocalisa-
tions.
To separate between random colocalisations and true interactions, to ’deconvolve’ them,
a monomeric control was measured using CD86. [38, 114, 115] This monomeric mem-
brane protein is not expected to interact with MOR. CD86 was co-transfected with wild-
type MOR bearing a N-terminal SNAP-tag. For two colour TIRF imaging the receptors
were labelled with SNAP 647 and Caco-Gly4-Cy3 respectively. Imaging and analysis
was done as described for the MOR-MOR cases. The interactions derived from CD86-
MOR are random, as no productive interactions should occur. Thus it is now known
what a colocalisation matrix looks like, if only random colocalisations are observed. In
the next step, the interaction matrix obtained from MOR-MOR was deconvolved with
the one from the control, CD86-MOR, using the Lucy-Richardson deconvolution. [116]
This gives an estimate of colocalisations that are due to real interactions. The raw and
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deconvolved data are shown in figure 4.7 A. In 4.7 B an exponential decay was fitted to
the fraction of true interactions, Fr(t), using
Fr(t) = Ftruee
−(koff+kloss)t (4.1)
it was thus possible to derive koff = 0.557 ± 0.207 s−1. Furthermore, the exponential
time constant τ was calculated to be 1.797 ± 0.487 s. The association rate can be
expressed as
d[D]ρ
dt
· Ftrue = kon[µ1]ρ[µ2]ρ (4.2)
where [µ1]ρ and [µ2]ρ are the monomer densities in each channel and d[D]ρ/dt the rate
of new colocalisations per area unit of area.
Assuming that at a long time scale, the formation and the dissociation rates reach an
equilibrium, the dimer density can be calculated as:
[D]ρ =
1
koff
d[D]ρ
dt
· Ftrue (4.3)
giving a fraction of dimers of 4.45 %. The association rate kon was then calculated
using:
kon =
d[D]ρ
dt
· Ftrue(
[Ch1]ρ − 1koff
d[D]ρ
dt
· Ftrue
)(
[Ch2]ρ − 1koff
d[D]ρ
dt
· Ftrue
) (4.4)
where kon = 0.020 ± 0.004µm2molecule−1s−1. Here the monomer densities are not
measured directly but calculated using the estimated dimer density from eq. 4.3
As a lot of receptors seem to stop while colocalising with another receptor, I checked
the possibility of colocalisation with clathrin coated pits (CCPs). To that end, I per-
formed the same set of experiment as described above but with co-transfection of GFP-
clathrin. The 200 frames recorded of the clathrin channel were stacked and the CCPs
were automatically located and fitted with a 2D Gaussian giving an estimated width
L for each individual pit. All receptor-receptor interactions that lasted longer than 20
frames (560 ms) were checked for colocalisation with a CCP. If one of the interacting
receptors was localised once within the L of a pit, the whole receptor-receptor interaction
was counted as ’inside’ a pit. If the interacting receptors were never localised within
any L of any pit, then the interaction was attributed to be ’outside’ of CCPs. Because
58
4.4. Investigation of dimerisation
CCPs are diffraction limited, the length L is larger than the actual size of the pits, there-
fore the fraction of inside pits was over-estimated, rather than under-estimated. Still
the analysis showed that 77± 9 % of receptor-receptor interactions happened outside of
CCPs, whereas 23± 9 % colocalise with a CCP, shown in figure 4.8.
Taken together, it could be determined that at a single-molecule level a small but per-
sistent fraction of MOR is present as homodimers. Furthermore, the majority of those
homodimers is present outside of CCP. It can be concluded from the analysis, that those
interactions are true and not an artefact of random colocalisation or internalisation pro-
cesses.
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Figure 4.7.: Results of the deconvolution. In A) the raw data of colocalisations of µOR with
µOR is shown (red). As a control the colocalisations of CD86 with µOR was
measured (blue). The raw data of µOR-µOR deconvolved with the CD86 control
is shown (green). The control deconvolved with itself should give in the optimal
case a single peak at 0 (cyan), here it is close enough. B) shows the deconvolved,
meaning ‘true‘ interactions, which were fitted giving a tau of 1.797± 0.487 s
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Figure 4.8.: Shown is a representative cell with tracked interactions overlaid on the clathrin
channel. Receptor-receptor interactions are shown in blue, receptors bound to
Caco-Gly4-Cy3 are depicted in green and bound to the CY5 variant in magenta.
The clathrin channel is represented in a heat map in grey scale with lighter colour
corresponding to higher amounts of GFP-clathrin. The red circles indicate the
located and fitted CCP. Inset A) shows very long receptor-receptor interactions
which colocalise even with several pits. In B), a typical interaction is visualised,
where the monomers diffuse normally and stop while interacting, but in this case
outside of CCPs.
61

5. Discussion
5.1. The set of new fluorescent ligands is specific and
easily detectable
The new fluorescent ligands for MOR and DOR were designed to be applicable for flu-
orescent microscopy methods and to be sub-type selective. In a first test, CHO were
transiently transfected with wild-type MOR or DOR . With TIRF imaging it was pos-
sible to achieve a high signal-to-noise ration so that the ligands attached to either Cy3
or Cy5 are easily detectable.
For the sub-type selectivity, both,the CACO and the naltrindole compounds were tested
on untransfected cells, as well as CHO cells transfected with the other sub-type. The
CACO fluorescent ligands only bound to cells expressing MOR while the naltrindole
compounds only labelled cells expressing DOR. Saturation binding experiments by a
collaboration partner in Montpellier (group of Se´bastien Granier) confirmed the high
sub-type selectivity as well.
Thus, it was confirmed that the chemically modified ligands retain properties of the
parent compounds, like the high sub-type selectivity, but also that the attached fluo-
rophores, Cy3 and Cy5, make them suitable for TIRF imaging.
5.2. Conjugation of linker and fluorophore changes
properties of the pharmacophore
CACO was previously reported by others as a sub-type selective, high affinity MOR
ligand with a kD of 0.52 ± 0.14 nM. [117] After the conjugation of tetraglycin as a linker
and Cy3 as fluorophore, not only the structure is changed, but also pharmacological
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properties. In figure 4.2 A both compounds, with either Cy3 or Cy5, show a loss in
affinity. With kD values of 87.29 ± 49 nM and 295.2 ± 141 nM respectively, the com-
pounds loose some of the affinity but retain a dissociation constant in the nM range.
Furthermore, McLaughlin et al. reported a wash resistance of 50 % for CACO using
[D-Ala2, N -MePhe4, Gly-ol]-enkephalin (DAMGO) for inhibition binding experiments.
[117] For the new ligands, the compound attached to Cy3 shows a small loss in wash re-
sistance to 34±4 %, whereas CACO attached to Cy5 retains it’s property with 54±3 %.
The differences to the parent compound CACO can be explained through the chemical
modifications - the Cy3 and Cy5 dyes both increase the size of the compounds. Never-
theless, the pharmacophores show decent pharmacological and photophysical properties,
making them suitable for single-molecule microscopy applications.
The same conclusion is true for the compounds designed for the DOR. They display
very high affinity with a kD in the one digit nM range for both, the Cy3 and the Cy5
compound. Thus, they experienced only a minor loss in comparison to the parent
compound naltrindole with kD ≈ 0.2 nM. [118] Similar to the MOR compounds the
naltrindole ligands possess wash resistance and as for MOR the Cy3 derivative has a
lower wash resistance (69 %) than the Cy5 compound with outstanding 93 %. With such
a high wash resistance, the ligand is nearly comparable with covalent labelling systems
such as the SNAP-tag.[38]
In general, it seems that wash resistance is a neglected property of fluorescent ligands,
as it is not expected to occur. To the best of my knowledge, the BODIPY derivative
of CACO is the only fluorescent MOR ligand reported to show wash resistance with
95 %. [119] This could be due to several factors. First, the ligands are not tested for
wash resistance, as it is not expected and might not show any relevance for the design
of the respective method, that the ligand is designed and used for (e.g. if the down-
stream signalling is investigated, GTPγS binding for example). Second, wash resistance
could prove disadvantageous in competition binding assays or other dynamic compar-
isons of ligands, and thus only fluorescent ligands without wash resistance properties,
and that are fully reversible, are reported. Third, there could be a problem in quantifi-
cation of the wash resistance, as it is often observed qualitatively and not quantitatively.
[117, 120, 121] Fourth, the wash resistance may be observed, but the advantage is not.
Therefore, this property is not reported and no efforts are made to improve the wash
resistance of fluorescent ligands.
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For single-molecule imaging and tracking, it is advantageous to have wash-resistant
fluorophores, as most labelling protocols include washing steps before the actual imaging.
This led, for example, to the development of labelling tags like SNAP and HALO (see
section 1.6). Those tags form irreversible covalent binding and lead to an extreme
high wash resistance. The disadvantage of those tags, however, lies in their need to be
encoded with the protein of interest, therefore differing from the wild-type receptor. In
contrast, wash-resistant fluorescent ligands have the advantage of not needing chemical
modifications of the protein itself while only the ligand is changed.
5.3. The opioid receptors show a heterogeneous
diffusion behaviour
After proving that the two sets of selective fluorescent ligands possess suitable prop-
erties, they were applied in single-molecule imaging. As Cy3 is more photostable than
Cy5, the compound Caco-Gly4-Cy3 was chosen for one colour experiments to investigate
the diffusion behaviour of wild-type MOR in CHO cells. The results show that 22 %
of receptors are virtually immobile. This means that a substantial fraction of receptors
does not show high mobility, as their movement is negligible in comparison to other
diffusive behaviours or is even so small that it cannot be resolved with our application.
[74, 78, 122] One reason could be that the particle stops for interactions with other pro-
teins, or that the receptors are trapped in a CCP and will be internalised soon. Some
receptors in the virtually immobile fraction may also be due to false detection, for exam-
ple if spots from the background are detected as receptors by the automated detection
and tracking scripts. For DOR labelled with naltrindole-Cy3, the fraction of receptors
showing nearly no diffusion was even higher, at 27 %.
Sub-diffusive motion was observed for 34 % of MOR and 38 % of DOR. Sub-diffusive
behaviour can arise from different effects, and means that over long periods of time the
particle is exploring less space than expected for normal diffusion, hence it’s a form of
anomalous diffusion. This can for example be due to interactions with the environment,
or because the membrane is too crowded. 34 % of the MOR and 27 % of the DOR showed
normal diffusion with an average diffusion coefficient of 0.12µm2s−1 and 0.15µm2s−1 re-
spectively.
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This leaves a fraction of 10 % for the MOR and 9 % for the DOR being super-diffusive.
Super-diffusion is also a form of anomalous diffusion and could for example be directed
motion. The results are comparable to previous findings from our lab for the α2A adren-
ergic receptor with 6 % of the receptors being super-diffusive. [74]
Important to note is that the ligand might influence the diffusion behaviour of the re-
ceptor. Tabor et al. demonstrated that different ligands influence the fraction of dimers
formed, as well as the diffusion coefficient of the receptors. [37] In the case of the
dopamine receptor, an antagonist increased the fraction of dimers and at the same time
slowed down the receptors, resulting in a lower diffusion coefficient. For both sub-types
of the opioid receptors, the fluorescent ligands were, at least long-term, antagonistic.
This could explain the higher fractions for virtually immobile and sub-diffusive motion
in comparison to the α2A AR reported by Sungkaworn et al., as the receptors could be
involved in dimer formation and dissociation. [74] In addition, the difference in ligands
can explain the difference between MOR and DOR - naltrindole is a pure antagonist,
whereas CACO is a short-term agonist and a long-term antagonist.
In a very recent study, Metz et al. investigated the mobility of MOR in AtT20 cells
stably expressing FLAG-tagged MORs labelled with quantum dots. [123] In the basal
state, Metz et al. observed that 33 % of receptors were virtually immobile, which is
significantly higher than the 22 % of the present study. [123] This can be explained by
the usage of quantum dots, which were proven to slow down the diffusion of receptors.
[124, 125] As described above, the presence of a ligand can also alternate the diffusion
behaviour. This was confirmed in the study of Metz et al., as they measured the mo-
bility under basal condition, after 1 minute treatment with DAMGO or morphine, and
after 10 minutes treatment with those agonists. In the case of DAMGO, the fraction of
immobile receptors decreases significantly after 1 minute treatment, and then increases
above the basal level after 10 minutes. This is a good indicator, that the mobility is
strongly dependent on the ligand, as well as on the time the receptor is exposed to the
ligand. Morphine on the other hand did not change the fraction of immobile receptors
after 1 minute but increased it after 10 minutes. It thus clearly indicates that the nature
of the ligand, and which signalling pathway it triggers, has an influence on the diffusion
behaviour. This was highlighted before by Melkes et al. using fluorescence recovery after
photobleaching (FRAP) on MOR in the presence of different biased ligands. [126]
A further explanation for the higher fractions of virtually immobile receptors in the
study of Metz et al. could be the different cell model. The mobility of receptors strongly
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depends on the membrane and how compact it is - the more densely packed, the slower
the particles, and the more sub-diffusion or even confined and immobile receptors can
be observed.
5.4. The mu opioid receptor is mostly monomeric
As discussed in the introduction ( section 1.3 and 1.4), dimerisation plays an important
role and is widely discussed for opioid receptors. Many studies were performed using
diverse techniques and different models which lead on the one hand to findings favouring
dimers [65, 66, 51, 67, 45, 68, 69] and on the other hand to findings favouring opioid re-
ceptors as monomers [63, 64]. The level of dimers can have an effect on the downstream
signalling or even trigger different pathways or internalisation processes, and thus influ-
ence the pharmacological response. A better understanding of dimerisation, especially
for the MOR, could lead to the development of pain killers with less side effects.
To investigate the possibility of MOR dimers, the Cy3 and Cy5 compounds of CACO
were used in two colour TIRF microscopy experiments on CHO cells expressing tran-
siently MOR. I found that most receptors are monomeric with a small, but persistent,
fraction of dimeric receptors. These receptor dimers likely arise from transient inter-
actions among MORs as implicated by the kon and koff times. The automated com-
putational analysis gave kon, koff and τ values which are comparable to other studies.
[74, 34, 37] With the receptor densities, kon ,and koff, the fraction of dimers was calcu-
lated to be 4.45 %. Sungkaworn et al. found values in the same range for α2AAR and Gαi
interactions after stimulation. [74] Together with the relatively long interaction times,
my findings indicate that the found fraction of dimers for MOR could be biologically
relevant. On a technical level, I was cautious to get a realistic estimation of dimer
populations and association rate kon. The experimental design allowed only the direct
observation of dimers labelled with two different ligands. Based on the direct observa-
tions, the fraction of dimers would have been underestimated. To also include dimers
consisting of two times the same colour (Cy3-Cy3 or Cy5-Cy5), koff was calculated from
the distribution of dissociation times (eq. 4.1). Likewise, kon (eq. 4.4) and the final
dimer density (eq. 4.3) were calculated based on measurable variables. However, the
assumption has been made that dimers cannot interact with further receptors to form
higher order oligomers.
The observed small fraction of dimers and the dissociation rate of 0.557±0.207 s−1 are in
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good agreement with the majority of the literature. Provasi et al. found no dissociation
events after dimer formation within their 10µs simulations. [68] The resulted koff from
my investigations is indeed several magnitudes larger than the time window of normal
CG MD simulations. However, it is important to note that it would not be feasible to re-
solve a dissociation rate in the µs range with a frame rate of 35µs. Meral et al. used MD
simulations in their recent study as well, and claimed that the fraction of homo-dimers
at physiological conditions is ‘negligible’. [64] In their simulations, the dimer lifetime
does not exceed ∼ 0.3 ms which is significantly smaller from the τ = 1.797±0.487 s in my
experiments. My findings differ from studies using BRET and co-immunoprecipitation.
This may be due to the different methods, using either cell destruction or far higher
expression levels. [35, 66, 51] Only the study of Wang et al. is contradicting my results
in part. In their study they found dimerisation happens before the trafficking of the
receptor to the cell membrane. [45] However, my study clearly exhibited dynamic for-
mation and dissociation of receptors within the membrane.
In my experiments, the majority of the particles seem to stop while interacting. To check
if the found dimers are artefacts from internalisation processes, the receptor-receptor in-
teractions were analysed for colocalisation with CCPs. As explained above, the presence
of CCPs was slightly overestimated. Thus, the fraction of dimers colocalising with CCPs
is probably smaller than the estimated 23 %. This is in agreement with a resent study
by Metz et al. where they report that 5 % of receptors under basal condition and 12 %
after 10 minutes stimulation with DAMGO colocalise with CCPs. [123]
It is possible that the formation of the dimer itself requires the receptors to stop. Thus,
it would be easier to find the right orientation and do conformational adjustments as
observed in some MD simulations. [64] It may also be due to interactions with other
proteins and effectors, as the study of Sungkaworn et al. also showed how receptors stop
within hot spots while signalling. [74] The presence of signalling hot spots could also
explain the discrepancies between MD simulations and results from in vitro experiments.
Accordingly, it would be worthwhile to investigate the nature of the dimer formation
further using different, and including biased ligands, ranging from full agonists to partial
agonists and antagonist, to reveal possible effects. This could give more insights into
the role of different signalling pathways in dimer formation.
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Part II - smFRET on α2A AR
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6. Results
In this project, I wanted to look at the activation process of GPCRs. Especially of
interest is the number of substates the receptor has, as recent studies suggested that
there could be more than just an active and inactive state. [1, 2, 3, 4] The α2AAR was
chosen as prototypical GPCR model and fluorescent single-molecule TIRF microscopy as
method. Investigations on a single-molecule level are advantageous to capture also short
lived or rare events. In ensemble experiments, those short or rare events get masked by
the more prominent states.
6.1. α2A AR with SNAP- and CLIP-tag
6.1.1. smFRET experiments
Testing dye combinations for smFRET
The chosen α2AAR has a CLIP-tag in the third intracellular loop and a SNAP-tag at the
C-tail. Thus, it was suitable for FRET studies as well as fluorescent single-molecule mi-
croscopy. In order to perform smFRET, different dye combinations were tested to select
the most promising FRET pair for measurements at the TIRF microscope. This means
clear signals, low background and good labelling properties. The pair needed to contain
one SNAP dye and one CLIP dye for orthogonal labelling of α2AAR-SNAP-CLIP mu-
tant. Furthermore, emission in red and far red were preferable for TIRF measurements.
These requirements led to the selection of 6 potential pairs:
• CLIP-Surface 647 + SNAP-Surface 5491
• CLIP-Surface 647 + SNAP-Surface Alexa 546
• SNAP-Surface Alexa 647 + CLIP-Surface 547
• SNAP-Surface 649 + CLIP-Surface 547
1In the text shorter names will be used like ’SNAP 549’
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• CLIP-Surface 547 + SNAP-Surface 488
• CLIP-Surface 647 + SNAP-Surface 488
CHO cells were transiently transfected for 24h with a CD86 construct bearing a N-
terminal SNAP- and CLIP-tag. This insured that both dyes are close enough for FRET
to occur once they are labelled, with the FRET distance up to 10 nm. The cells were
labelled sequentially with the dyes, washed and then imaged at the TIRF microscope.
Both, acceptor and donor channel were checked for successful labelling. Images were
acquired by only illuminating the donor with a laser power of 15 % with either a 488 nm
or a 561 nm diode laser.
The signal detected in the acceptor channel is a mixture of direct excitation, bleed
through from the donor channel and FRET. The results of all 6 pairs tested are shown
in figure 6.1. Using CLIP 647 as acceptor dye and either SNAP 549 or SNAP Alexa
546 as donor gave the best results, with respect to high signal-to-noise ratio, labelling
efficiency and specificity. For those combinations, dynamic behaviour of single-particles
was observed in the acceptor channel. With SNAP 488 as donor nearly no signal was
observed for CLIP 647. In combination with CLIP 547 as acceptor for SNAP 488, the
signal was very dim and not as sharp and bright as seen for the red/far red combina-
tions. Taking CLIP 547 as donor and SNAP 649 as acceptor gave acceptable results,
but CLIP 547 showed a higher background than other dyes. This was also observed
in combination with SNAP Alexa 647, which gave better results than SNAP 649, but
still the background from CLIP 547 was too high and the acceptor signal lower than for
SNAP 549/CLIP 647. Thus, SNAP 549 as donor and CLIP 647 as acceptor dye were
chosen for further experiments.
Detection of smFRET events
To investigate the activation process of a prototypical GPCR, the α2AAR mutant with
a CLIP-tag in the 3ICL and a N-terminal SNAP-tag was chosen, as mentioned before.
This receptor was chosen as it showed high FRET efficiencies with CFP and YFP. [23]
Replacing the FPs with labelling tags at the intracellular side of the receptor presented a
challenge. Therefore, different approaches were tested. A first way to achieve intracellu-
lar labelling was to electroporate CHO cells for transfection and simultaneously adding
the acceptor and donor dyes. Thus, the cells would incorporate the plasmid and the
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SNAP 549CLIP 647 CLIP 647 SNAP 546
SNAP 647 CLIP 547 SNAP 649 CLIP 547
CLIP 547 SNAP 488 CLIP 647 SNAP 488
10 µm
Figure 6.1.: Comparison of different dye combinations. For each possible FRET pair the ac-
ceptor channel is shown to the left and the donor channel on the right. For all
images only the donor was excited.
dyes. Once the cell starts the expression, the dyes could label the receptors. However,
this approach turned out to be too stressful for the cells and not efficient enough. Too
less dye was taken up during electroporation, resulting in very poor labelling.
At the beginning of this project, the number of commercially available cell-permeable
dyes was limited. In this case two good cell-permeable dyes would have been needed for
orthogonal labelling and emission in red and far red.
Another approach of labelling the intracellular side of the receptor was the preparation
of supported membranes (see section 3.2.8). [113] Therefore, the glass coverslips were
coated with PLL before seeding CHO cells. The transfection was performed as before us-
ing Lipofectamine and after 4 h supported membranes were prepared as described in sec-
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tion 3.2.8. Such a short transfection time did not allow to obtain supported membranes.
To overcome this limitation, a stable cell line was created with the α2AAR construct
containing the CLIP- and SNAP-tag, which I called ’Altair’. Altair cells showed differ-
ent expression levels ranging from very low, suitable for single-molecule experiments, to
very high expression. The preparation of supported membranes with Altair cells was
successful and reproducible. Before TIRF imaging, receptors were labelled with SNAP
549 and CLIP 647. The acceptor dye CLIP 647 was tested for direct excitation with the
561 nm diode laser as well as for the bleed through from the donor SNAP 549 into the
acceptor channel. Both effects were very low and negligible in comparison to the signals
acquired in experiments.
To reduce receptor bleaching and blinking, a special smFRET buffer with an oxygen
scavenging system was used. To prevent new oxygen leak into the buffer, the coverslips
were placed on top of 200µm thick double sided tape and sealed with nail polish. In
figure 6.2 a supported membrane from Altair cells labelled with SNAP 549 and CLIP
647 excited at 561 nm is shown. In the merged image, particles that are present in both
channels simultaneously appear yellow. The acceptor in this case is excited by radia-
tionless energy transfer from the excited donor, meaning that FRET occurs.
5 µm
Donor MergedAcceptor
Figure 6.2.: Supported membrane of Altair cells showing smFRET events. On the left is the
donor channel, with a directly excited supported membrane of Altair cells. In the
middle is the corresponding acceptor channel with single receptors being clearly
distinguishable above the background. On the right a merged figure is shown with
donor depicted in green, acceptor in magenta. Receptor emitting in both channels,
due to FRET, appear white in the merged image.
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A zoom-in of a smFRET event is shown in figure 6.3. In the beginning, the par-
ticle appears red, which represents acceptor emission. The particle moves some time
before it switches to green, which represents donor emission. In this event, the loss of
the red signal and smFRET event is likely due to the photobleaching of the acceptor dye.
1 µm
Figure 6.3.: Switching of smFRET event. Shown are frames of an α2AAR switching between
FRET states. First two frames the receptor is in a high FRET state emitting
mainly far red (acceptor), here depicted in red. In the third frame the receptor
switches the FRET state exhibiting a mixture of donor and acceptor emission,
green and red, appearing in this merge yellow. Afterwards the receptor continues
moving and emitting mainly in the donor channel, green.
Different environments to shift the receptor into different substates
The receptor activation process depends on the presence of ligands and nucleotides.
Thus, the environment of the receptor has direct impact on the activation process. As
described in the introduction, 1.2, nucleotides, agonists or antagonists can shift the free
energy landscapes for the different substates of the receptor. I wanted to use those differ-
ent conditions to push the system into different substates and to investigate how many
there are. To this aim, supported membranes of Altair cells were imaged under different
conditions: basal without nucleotides, stimulated without nucleotides, basal with nu-
cleotides and stimulated with nucleotides. As an agonist for α2AAR norepinephrine was
used at a saturating concentration of 100µM, while yohimbine (100µM) was used as an
antagonist, and as nucleotide 10µM GTPγS. To control the presence of nucleotides, the
membranes were treated for 30 minutes before imaging with apyrase, an enzyme that
hydrolyses nucleotides.
The single-molecule movies were tracked and analysed. Therefore, a script was written
to sort detected particles and to identify particles that are present in acceptor and donor
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channel simultaneously at the same area. For those particles, emitting in red and far
red, the intensities were plotted over time like shown in figure 6.4. The signal-to-noise
ratio was too low for further analysis of smFRET events.
After apyrase treatment, a further decrease in the signal-to-noise ratio was observed,
hence no further analysis was pursued.
A B C
D E F
G H I
Figure 6.4.: Trajectories and intensities of smFRET events. Shown are nine different smFRET
events observed after apyrase treatment and yohimbine stimulation. Always on the
left are the trajectories depicted, on the right the fluorescent intensities.The donor
is shown in green, the acceptor in magenta. A to C show events of donor emission
with stepwise changes in intensity. In D to I examples of switches between donor
and acceptor excitation are represented. From the trajectories it can be seen how
the receptors in both channels got assigned as the same receptor. Especially in G
and H the trajectories are continued by the acceptor channel (magenta) when the
donor emission (green) stops.
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6.1.2. Testing the functionality of the construct
Setting up a FRET set-up with exchangeable filter sets
To test the α2AAR construct with SNAP- and CLIP-tag in ensemble FRET measure-
ments, and to be able to compare the results with those obtained with smFRET at
the TIRF set-up, a new FRET set-up was needed. At the TIRF microscope smaller,
brighter and stable organic fluorophores are used, mainly emitting in the red and far-red
spectrum of the visible spectrum. However, the FRET set-ups available at the institute
were only equipped for measurements using CFP, YFP and GFP. Hence, the new FRET
set-up needed to be equipped with filters, that match our requirements and to be easily
exchangeable to allow a more flexible choice of fluorophores. Therefore, an Axiovert 200
from Zeiss was reassembled and modified. The light path for the emission was extended
and a holder for exchangeable filter cubes was installed in front of the two detectors.
The excitation filter-sets were already easily exchangeable as they can be mounted into
a filter wheel. A scheme of the set-up is shown in figure 6.5.
The filters and beam splitters were chosen deliberately, taking into account the ex-
citation and emission profiles of donor and acceptor dyes to achieve a balance between
efficient donor excitation, maximum read-out of the emission and limiting bleed through,
direct acceptor excitation and cross-talk. The thus assembled filter-sets can be found in
table 6.1.2.
Furthermore, an old perfusion system was cleaned, re-assembled and put in place to
enable dynamic measurements with ligand stimulations and washing steps.
Table 6.1.: Filter-sets for the re-assembled FRET set-up
Name filter-set Filter 1 Beam splitter Filter 2
CFP-YFP Donor-Set 436/20 455 -
CFP-YFP Acceptor-Set 504/12 515 535/30
488-546 Donor-Set 472/30 495 -
488-546 Acceptor-Set 546/10 555 595/40
546-647 Donor-Set 542/20 555 -
546-647 Acceptor-Set 635/18 649 -
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Figure 6.5.: Scheme of the FRET set-up. A xenon lamp is used as a white light source from
which a monochromator is used for wavelength selection. A clean-up excitation
filter (F1) is placed before a dichroic mirror (DC1). The excitation light for the
donor is reflected to the specimen from which emitted light from donor and accep-
tor can transmit through the DC1. A small part of the emitted light is deviated
to a camera for visualisation and region selection for experiments. The majority
of the emitted light is divided by a second dichroic mirror (DC2) specific for the
donor-acceptor couple in use. The thus divided light passes through acceptor fil-
ters (F2 and F3) before it is detected. The signals are simultaneously visualised
at a computer from which the experiment can be controlled.
Ensemble FRET measurements with SNAP-CLIP-construct
The smFRET events qualitatively observed in TIRF experiments could be due to arte-
facts. To test if those events were relevant, the construct was tested in ensemble FRET.
In ensemble measurements a change in FRET signal should be observable after stimu-
lation, comparable to the responses observed with CFP and YFP as FRET pair. [23]
HEK T cells were transfected using effectene for 48 hours with the same construct
stably expressed in Altair cells. As a control α2AAR with CFP and YFP was transfected.
The SNAP-CLIP construct was labelled with CLIP TMR and SNAP SiR. At the newly
reconstructed FRET set-up, this dye combination proved to be challenging. High signals
could be observed for the donor channel, emitting red light, but nearly no signal could
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be measured for far red (SNAP SiR). Tests with HEK T cells overexpressing CD86 with
N-terminal SNAP- and CLIP-tag were used as control. Overexpression and successful
labelling was confirmed at the TIRF microscope but the signal in the FRET set-up still
remained absent. Different dyes emitting in far red were tested but no promising candi-
date was identified. Thus, the experiment performed at the TIRF microscope could not
be tested directly with ensemble FRET.
Functional testing with Gi-Sensor
To overcome the limitations of the far red in ensemble FRET measurements, a differ-
ent approach was chosen to test the functionality of the α2AAR construct. Therefore,
the activation of Gi protein was investigated using a Gi sensor. [127, 74, 24] Wild-type
α2AAR was used as positive control. Gi sensor and α2AAR constructs were co-transfected
via effectene in HEK T cells and imaged after 48 hours at the above described FRET
set-up. Cells expressing the Gi sensor at the cell surface were stimulated with increasing
concentrations of norepinephrine (10 nM − 100µM). The wild-type α2AAR showed in-
creasing activation of Gi proteins with increasing concentration of norepinephrine. For
the mutant with SNAP- and CLIP-tag even for saturating concentration no FRET sig-
nal could be observed (figure 6.6). These tests with Gi sensor were performed by Dr.
Marie-Lise Jobin (AG Calebiro, Institute of Pharmacology, University of Wu¨rzburg).
Functional testing with GTPγS binding assay
Another approach to test the functionality of GPCRs is the GTPγS binding assay with
the radioactive sulphur isotope 35S. This assay requires larger amounts of sample and
several controls need to be included. Furthermore, different constructs were planned to
compare. In addition, those samples should be tested under different conditions, basal
and stimulated either with agonist or antagonist. Activated G-proteins bind GTP and
are inactivated upon hydrolysis of the nucleotide to GDP. The GTPγS cannot be hy-
drolysed, at least not at a detectable rate, thus trapping the G-protein in an activated
state. The G-protein can just be activated and bind GTPγS if the receptor is functional.
Accordingly, if bound GTPγS can be detected by a scintillator, it indicates that the G-
protein got activated by an activated receptor. [128, 129, 130, 131]
Several trials were performed but the results were not as promising to justify the effort
in comparison to other methods like the Gi sensor, described above.
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Figure 6.6.: Results of the functional testing with Gi sensor. A) α2AAR with CFP and YFP
with norepinephrine stimulation. B) the wild-type α2AAR Gi response after nore-
pinephrine stimulation as positive control, showing that the Gi sensor works. C)
negative control with pcDNA and Gi sensor. D) α2AAR construct with SNAP and
CLIP tag showing no Gi activation after stimulation. The traces are representative
of three independent experiments.
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6.2. α2A AR with SNAP-tag and an unnatural amino
acid
6.2.1. Generation of 5 different mutants with unnatural amino acid
The α2AAR with SNAP- and CLIP-tag did not show any functionality, neither in ensem-
ble FRET experiments nor in tests with the Gi sensor. For this reason, an alternative
labelling strategy was explored. To minimise the effect of the incorporated tag on the
functionality of the receptor I tried to replace the tag in the 3ICL with an unnatural
amino acid. The unAA could later be fluorescently labelled via click chemistry (section
1.6). The selected insertion site should not affect the G protein binding or destabilise
the structure of the receptor. Previous experiences from the Sauer group (Biotechnology
and Biophysics, Biocenter, University of Wu¨rzburg) showed lysine and serine residues
are preferable to be replaced with an unAA (unpublished data). For this reason, 5 dif-
ferent possible sites were selected. One at the beginning of the 3ICL (lysine 327), one
relatively in the middle of the loop (serine 347), and three towards the end, close to
helix 6 (serine 360, lysine 370 and threonin 373). The SNAP-tag in the C-tail was kept.
Thus, it served as a reliable control to check the proper expression of the full length
receptors and later on as the labelling site for the second fluorophore for smFRET stud-
ies. The cloning was performed as described in section 3.2.3 by Ulrike Zabel (Institute
of Pharmacology, University of Wu¨rzburg).
Both tags are on the intracellular side. Consequently, the labelling has to be performed
with either two efficient cell permeable dyes or on supported membranes (section 3.2.8).
As of today, there are no efficient cell permeable dyes for click labelling yet available,
hence it was evident that supported membranes would be needed. As seen before, the
development and use of stable cell lines facilitates the preparation of supported mem-
branes and improves their reproducibility (section 6.1.1). Thus, five stable cell lines
were created expressing each one of the constructs in CHO cells and all five were suc-
cessfully generated (see table 6.2.1). Without the additional transfection of tRNA and
synthetase, the protein synthesis will stop at the amber codon, resulting in a truncated
receptor. In this work, a receptor that successfully incorporated the unAA is referred
to as full length receptor. There was the concern, that stable cell lines expressing trun-
cated receptor could be unhealthy. However, all new cell lines grew as untransfected
CHO cells, only the cell shape slightly differed as the cells grew more long than wide.
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Table 6.2.: Overview of stable cell lines and which plasmid they contain.
Name of the cell line Construct
Bellatrix α2A-K327amb-SNAP
Capricorni α2A-S347amb-SNAP
Deneb α2A-S360amb-SNAP
Enif α2A-K370amb-SNAP
Fafnir α2A-T373amb-SNAP
6.2.2. Comparison of constructs via SNAP labelling
The different mutants in the stable cell lines needed to be tested. On the one hand it
needed to be checked, if they can express the full length receptor. On the other hand,
I also wanted to compare the different mutants to choose the most promising construct
for further experiments. For this purpose, the stable cell lines were transfected with
the tRNA and synthetase construct and the medium was supplemented with TCO as
unAA to express the full length receptor containing the unAA. To check whether the
transfection worked and to compare the different cell lines, the cells were then labelled
with SNAP silicon-rhodamine (SiR), a cell permeable dye. Only if the unAA was incor-
porated successfully the full length receptor is synthesised including the SNAP-tag at
the C-terminus. The C-terminal labelled cells were imaged at a TIRF microscope.
The different stable cell lines showed different transfection efficiencies. Bellatrix dis-
played the highest transfection efficiency and the cells also showed different expression
levels among themselves (see figure 6.7 A). For Capricorni and Deneb (B and C in figure
6.7 respectively) it appeared that less cells were expressing the full length receptor and
comparably more ’ghost’ cells were seen. This means that the cells were internalising the
dyes without labelling the receptors. Thus, the dye was diffusing freely in the cytosol,
which is an indicator that the cells are unhealthy. This was even more eminent for Enif
cells (figure 6.7 D). For the Fafnir cell line no cells with full length receptor could be
found. These results showed that Bellatrix is the most promising candidate and was in
consequence chosen for the experiments thereafter.
82
6.2. α2A AR with SNAP-tag and an unnatural amino acid
10 µm
A
DC
B
Figure 6.7.: Stable cell lines expressing full length receptors labelled with SNAP SiR. Shown
are four of the five stable cell lines with amber mutation. In A) Bellatrix cells are
shown with different expression levels. B) shows a Capricorni cell with very low
expression level. C) is a cell from the Deneb cell line whereas D) shows a labelled
Enif cell. Both Deneb and Enif had a similar expression level as Capricorni. For
Fafnir no cells with full length receptor were found.
6.2.3. Comparison of expression levels of truncated and full length
receptors via western blotting
To check the expression levels of the stable cell lines for truncated and full length re-
ceptor (after addition of tRNA/synthetase and TCO), western blots were performed.
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First, the stable cell lines were stained with an HA-tag primary antibody without trans-
fection for full length receptor, to just compare the expression of truncated receptors.
This served as a second control to check whether the creation of the stable cell lines
was successful. As the western blot in figure 6.8 shows, the stable cell lines all express
truncated receptors and even though their lengths differ just in a few amino acids, the
difference in size can be seen.
Figure 6.8.: Western blot of the different stables cell lines. Lysates of untransfected CHO cells,
a positive HA-tag control, Altair, Bellatrix, Capricorni, Deneb, Enif and Fafnir
were loaded and detected with an HA-tag antibody.
From the tests with SNAP labelling, the stable cell line ’Bellatrix’ was chosen as most
promising candidate. Accordingly, those cells were taken for further tests to optimise
the transfection protocol with Jet-Prime (section 3.2.7) and the plasmid for the tRNA
and synthetase. In figure 6.9 it can be seen, that with transfection and addition of TCO
the lanes with Bellatrix get additional signal contributions at bigger molecular weight
going up to the size of Altair cells, which corresponds to the full length receptor with
SNAP- and CLIP-tag. However, for none of the tested conditions a clear second band
was observed. Without transfection of tRNA and synthetase, those signals are absent
(compare figure 6.8) and also for Enif with transfection, those contributions are not
present. Those contributions seen in transfected Bellatrix cells could be an indication
for longer fragments of the receptor, meaning that the protein synthesis progresses be-
yond the stop codon but terminates at different positions before the full length receptor.
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To better distinguish the full length receptor from the truncated one in western blots,
a SNAP antibody was tested. Unfortunately, this antibody provided a western blot
with high amount of unspecific bands even in untransfected CHO cells, hence I did not
proceed experiments with this antibody.
Figure 6.9.: Western blot of different transfections of Bellatrix (Bella) and Enif. Bellatrix cells
were seeded at increasing densities and then transfected with tRNA/synthetase to
express the full length α2AAR. In the last lane transfected Enif cells were loaded.
6.2.4. Click labelling of unnatural amino acid
An important and necessary step is the successful click labelling of the unAA, to in-
troduce the second dye. Before attempting click labelling on transfected Bellatrix cells,
coverslips from the same transfection were labelled with SNAP SiR to check for sufficient
transfection levels of full length receptors. If transfection proved satisfactory, supported
membranes were prepared and labelled afterwards with click TAMRA before imaging at
a TIRF microscope. In figure 6.10 Bellatrix cells expressing the full length receptor are
shown labelled with click TAMRA. All cells were very bright, showing a high expres-
sion level of the receptor containing the unAA. Regions outside of cells showed a high
background as well, indicating unspecific binding. Furthermore, the cells appeared to
be more intact than supported membranes, which means TAMRA is cell permeable to a
significant degree and the preparation of supported membranes did not work properly.
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As high background from unspecific binding was observed, it was not possible to distin-
guish cells with a lower expression level, and several washing steps did not improve the
signal-to-noise ratio.
Due to overall low transfection efficiency and time limitation, no further improvements
could be made.
10 µm
Figure 6.10.: Three representative images of click labelled Bellatrix cells. Bellatrix cells trans-
fected with tRNA/synthetase for the incorporation of an unAA into α2AAR click
labelled with TAMRA.
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7.1. Is the SNAP/CLIP-tag construct for α2A AR good
enough?
7.1.1. Detection of smFRET experiments with SNAP/CLIP-tag
construct
For the investigation of the activation process of GPCRs the α2AAR was chosen with
SNAP- and CLIP-tag. Thus, it was suitable to perform two colour labelling and test for
smFRET events. Looking at a single-molecule level would help to capture short-lived
or rare events, which are obscured in ensemble measurements.
Before testing smFRET on α2AAR in cells, different SNAP- and CLIP-dyes were tested
to select the most promising combination. With a CD86 with N-terminal SNAP- and
CLIP-tag next to each other, a control was chosen that assures that donor and acceptor
fluorophore are in a proximity, that allows for FRET to occur. From the tested combi-
nations SNAP 488 plus CLIP 647 gave the least acceptor signal. This can be explained
by the big gap between the spectra, all other combinations had a more significant spec-
tral overlap. Even though differences could be observed CLIP 547 showed comparably
high background, indicating poorer labelling specificity. SNAP 488 plus CLIP 547 gave
less sharp images compared to red/far red combinations. Thus, the decision was made
to either use SNAP 549/CLIP 647 or SNAP 546/CLIP 647. Both gave very similar
results with just a slight advantage for SNAP 549 over SNAP 546. In addition, SNAP
549 was more commonly used at the lab. As a result, SNAP 549 and CLIP 647 were
identified as most promising dye pair for smFRET experiments at our TIRF microscope.
One major challenge was to achieve high labelling efficiencies for the α2AAR construct
with intracellular SNAP- and CLIP-tag. To this aim, a stable cell line was created with
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this construct, Altair cells, from which supported membranes could be prepared. Sup-
ported membranes served as a solution for the intracellular labelling problem, but their
preparation was not always successful. In successful experiments also just ≈ 10− 20 %
of cells were turned into supported membranes. This was a limiting factor, as it reduced
the number of cells with appropriate receptor density per coverslip further. Additionally,
supported membranes are not as stable as intact cells. After preparation, the next steps,
including imaging, needed to be fast and efficient.
In addition to solving the intracellular labelling problem, supported membranes en-
abled the manipulation of the environment of the receptor. As described before, the
environment with ligands and nucleotides plays an important role. Ligands, can shift
the probabilities of different receptor conformations. In addition, nucleotides can help
trapping the receptor in a specific conformation. To have control over the nucleotides
present, apyrase was used before experiments. Apyrase is an enzyme that hydrolyses
nucleotides.
The working hypothesis was to shift/trap the receptor to different conformational states
using different ligands or nucleotides. This was shown before successfully by [6, 132, 18].
However, the apyrase treatment was another stressful experimental step for the delicate
supported membranes. Additionally, it was a time consuming step further prolonging
the protocol. Afterwards, the coverslip with the sample was mounted on a sample slide
with smFRET buffer containing an oxygen scavenging system. The whole sample was
sealed with nail polish. Those treatments increased the stress on the sample even more.
While imaging, one could observe by eye that the membrane patches become more stiff,
and the movements slower, until the patches became static. For the experiment only
the intact membrane patches with moving single receptors were acquired. Due to the
toxicity of the smFRET buffer, the sample had to be exchanged fast.
Having identified and selected a suitable dye pair, succesfully prepared supported
membranes, and utilised an oxygen scavenging system, a protocol was thus established
for smFRET imaging. With that protocol smFRET movies could be acquired at the
TIRF microscope. With labelled membrane patches from Altair cells, clear single recep-
tors could be observed moving in the acceptor channel upon donor excitation. Those
signals were more prominent and stood out in comparison to what was seen in the
controls for bleed through or direct excitation (acceptor excitation by the donor laser).
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These results were reproducible. However, just very few receptors were very bright in
the acceptor channel. This can be due to different reasons. On the one hand, it could
be, that most of the receptors were in a low FRET state. In this case meaning activated
as the TM6 and the C-terminus are far apart. Only receptors with a closed G-protein
binding site would exhibit high FRET states. It is likely that the lower FRET state, as
expected for the activated receptor, is not bright enough to be distinguished by eye. On
the other hand, it could be possible that the receptor mutant has an impaired function-
ality. In this case, it would be hard to see any changes in FRET. However, this would
also depend on the type of problem. It could still be that just a few receptors function
normally whereas the majority is dead and not undergoing any conformational changes
any more.
To test the existence of different substates and if their equilibrium can be shifted, differ-
ent conditions were employed to the membranes. The first step was an apyrase treatment
to hydrolyse all nucleotides. Next, samples were measured in the presence of different
ligands. Norepinephrine was chosen as agonist and yohimbine as antagonist. The antag-
onist was hypothesised to shift the equilibrium to the higher FRET state, corresponding
to an inactive conformation. With norepinephrine the receptor is activated. Thus, the
probability to find the receptor in an open conformation for G-protein coupling is in-
creased. Likewise, the supported membranes were measured with different nucleotides:
either GDP or GTPγS. The latter cannot be hydrolysed, hence trapping the G protein
in an activated state and coupled to the receptor. This results in a low FRET state.
Whereas an abundance of GDP has the opposite effect, trapping the Gα subunit in the
inactive form.
The acquired single-molecule movies were analysed using automated particle detection
and tracking. Afterwards, a routine was implemented to combine and identify particles
that appear in donor and acceptor channel simultaneously. Of those particles the in-
tensities and trajectories were plotted for further analysis. From the first results, it
appears that the signal-to-noise ratio is not high enough to distinguish between several
substates. If the quality of the data would have been better, a Hidden Markov model
would have been applied. This would allow to identify the number of substates present
without a priori estimations. Yet, the data acquisition needs to be improved before the
data processing can be improved and further customised.
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7.1.2. SNAP/CLIP-tag construct does not have any functionality
The qualitatively observed smFRET events in TIRF experiments needed to be con-
firmed. Else, it could be that the events were artefacts and not relevant for the in-
vestigation of receptor activation. The functionality of the receptor can be tested in
ensemble FRET measurements. Only if the receptor can be activated by ligands and
displays conformational rearrangements, can changes in the FRET signal be observed.
In order to perform those tests, a set-up was needed suitable for the FRET pair emitting
in red and far red.
As described in section 6.1.2, an old FRET microscope was modified and adapted. The
set-up is equipped now with exchangeable filter sets for different FRET pairs, expand-
ing the freedom of choice of fluorophores. The new FRET set-up is routinely used in
the lab for different projects, amongst which one contributed already to a publication
(Sungkaworn et al., [74]). With the external emission filter cubes in combination with
the filter wheel for excitation filters, the set-up is easily and quickly adaptable to dif-
ferent fluorophores that are used. Furthermore, the perfusion system with 8 different
reservoirs allows for dose-response curves over a wide range of concentrations or to com-
pare different ligands within one experiment. The projections of the region of interest
to a screen served advantageous while searching cells with high surface expression and
additionally in testing the flow from the perfusion system. The whole set-up was fully
functional within a few months.
The signals observed at the TIRF microscope, which look like smFRET events, needed
to be confirmed. Therefore, the functionality of the α2AAR construct with SNAP and
CLIP-tag was tested in ensemble FRET experiments. If FRET could be observed in
receptor-overexpressing cells, than the probability is high, that the observed events at
TIRF are smFRET events. To achieve a maximal signal, the receptor was overexpressed
for 48 hours in HEK T cells. These cells were chosen because they exhibit a high mem-
brane expression. CLIP TMR and SNAP SiR were chosen as fluorophore combination.
Both are cell-permeable and thus offer the advantage of bypassing the preparation of
supported membranes. Preparation of supported membranes in transiently transfected
cells has proven before already to be not feasible. With CLIP TMR and SNAP SiR the
absorption and emission spectra were still very close to the smFRET pair SNAP 549
and CLIP 647.
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Even though the new filter sets for the FRET set-up were planned for FRET pairs emit-
ting in red and far red, no signal could be detected in far red. To rule out a labelling
problem, control cells overexpressing the receptor and labelled with SNAP SiR were
imaged at the TIRF microscope, which is significantly more light sensitive. The TIRF
images confirmed that the receptor was overexpressed and also labelled succesfully. Ac-
cordingly, the detection at the FRET set-up must have been the problem. Thus, it was
not possible to perform ensemble FRET experiments and to look at the direct activation
under norepinephrine stimulation.
To overcome this limitation, the Gi sensor was chosen. The sensor shows a drop in
FRET upon Gi activation. Gi is activated by the activated receptor, thus requiring the
conformational changes, that we wanted to look at initially. Showing that the G-protein
activation is still working, would prove that the receptor did not lose its functionality.
The Gi sensor contains a CFP and YFP as FRET pair and could be used without further
modifications at the new FRET set-up. Wild-type α2AAR was co-transfected with the
Gi sensor as a control. Upon stimulation the FRET signal decreased, confirming that
the sensor works reliably at this set-up. It was even possible to distinguish differences in
the FRET signal with increasing norepinephrine concentration. However, with α2AAR
SNAP and CLIP-tag no FRET signals were observed.
This is a concerning indication, that the SNAP and CLIP-tag construct lost its func-
tionality. Still, other explanations could be possible, too. Even though the expression
of the sensor was directly observed by CFP and YFP emission, there was no control for
co-expression of the sensor and α2AAR . Even though the control with wild-type α2AAR
worked well, it is not necessarily the case, that both plasmids express comparably. The
plasmid for wild-type α2AAR can have higher (co-) transfection efficiency. Thus, the
chance of measuring a cell co-expressing sensor and receptor would be higher. If the
plasmid with the inserted SNAP- and CLIP-tag performs weaker for co-transfection, it
is possible that only cells expressing the sensor were imaged. Thus, the sensor could not
show FRET changes, as it could not be activated by a receptor.
After all, the functionality of the SNAP- CLIP-tag α2AAR construct could not be con-
firmed, neither with ensemble FRET nor with the Gi sensor. This might be the result
of technical problems, especially for the ensemble FRET. Nevertheless, a solution to
recover the functionality of the receptor was needed.
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7.2. Does the insertion of an unAA solve the problems
of the SNAP/CLIP construct?
7.2.1. Successful insertion of amber codon
The α2AAR construct with CLIP- and SNAP-tag did not show any functionality. For-
mer publication using CFP and YFP demonstrate, that the insertion of tags in the third
ICL and the C-tail are possible without loosing the functionality. Nevertheless, a tag
is always a change in the receptor and the effect of the insertion should be minimised.
One way to achieve this is to minimise the size of the tag itself. Another way, to try
different insertion sites. Accordingly, I tried to use an unAA instead of the CLIP-tag in
the third ICL. Thus, minimising the size of the tag dramatically to just one amino acid.
In addition, I tried five different insertion sites.
Five stable cell lines were created, each expressing one of the five different amber mu-
tants. A first indication, that the creation was successful was the acquired gentamicin
resistance. This could just be observed, if the cells stably express the truncated α2AAR
with a stop codon in the third ICL. The new cell lines grow like CHO cells, only the
shape differs slightly. This indicates that the over expression of a truncated receptor
does not affect the health of the cells, as far as can be seen by the morphology. Fur-
thermore, it was proven in western blots, that the different cell lines are expressing the
truncated receptor, bearing a HA-tag, and that the length of the truncated receptor
differs between the cell lines. Even the difference of a few amino acids in length could
be observed in western blots. Moreover, the different cell lines show similar expression
levels. This, however, can just serve as an indicator as cells are pooled together for the
lysate preparation and amongst those cells the variability of expression levels can still
be high.
The creation of a stable cell line expressing the full length receptor was not considered
as this would require orthogonal antibiotic resistances for the plasmid of the receptor
and the plasmid encoding for the tRNA and synthetase. Thus, only one transfection
was needed for further experiments. However, as the transfection with Jet Prime for the
tRNA and synthetase construct lasts 48 hours, the cells have enough time to rest and
recover before the preparation of supported membranes. In addition, co-transfection
together with the receptor constructs was expected to lead to a high over expression,
which is not desirable for single-molecule experiments.
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The new stable cell lines were tested for the expression efficiency of full length recep-
tors after transfection with tRNA/synthetase and the addition of TCO to the medium.
After SNAP labelling, the cell lines showed differences amongst each other. The cells
with the best transfection efficiency and also different expression levels were Bellatrix.
Only a few ghost cells were detected but their level was minor and in most cases even
lower than for the other cell lines. Interestingly, the efficiency decreases the later the
amber codon is introduced in the receptor. For Bellatrix, the stop codon is at the be-
ginning of the 3ICL. In the case of Enif and Fafnir, the point mutation was introduced
at the very end, close to the sixth αhelix. In comparison to the location within the loop,
the type of amino acid, that got replaced, seems to have a lesser influence. In both,
Bellatrix and Enif, a Lysine was replaced with an amber codon. Bellatrix shows clearly
better transfection efficiencies. For Capricorni and Deneb, a Serine was mutated, both
show comparable efficiencies and expression levels. For Fafnir, it remains unclear why
it showed negative results. It could be the position close to TM6 or it could be the
threonine, that got replaced, probably both had an influence on the expression. Fur-
thermore, it is important to note that Eason et al. showed that parts of the ICL3 is
necessary for G-protein coupling. [133] In their study, they changed complete domains.
Still, changing one amino acid within the domain could lead to the impairment of Gs
coupling. The mutation sites of Deneb, Enif and Fafnir are in this domain. coupling to
Gi should not be effected according to the finding of Eason et al.. [133]
To test the ratio between truncated and full length receptor, western blots were per-
formed. For this reason, Bellatrix and Enif cells were transfected with tRNA/synthetase
to get expression of the full length receptor. The western blot shows clear bands for the
truncated receptor at the same level seen before for the untransfected cell lines. Addi-
tionally to this clear signal, the Bellatrix cells show signals for bigger protein fractions.
This might be an indication, that receptor synthesis in the ribosomes continues beyond
the introduced stop codon. Those contributions are totally absent for Enif. This ob-
servation is in good agreement with the results from the SNAP labelling. At the TIRF
microscope Bellatrix cells demonstrated a higher probability to express the full length
receptor than Enif cells. This strengthened the choice of Bellatrix as the most promising
candidate for further experiments.
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7.2.2. Bellatrix expression levels are still not high enough for
smFRET experiments
The amber mutant expressed in Bellatrix cells was chosen as most promising candidate.
In TIRF imaging it exhibits the highest transfection efficiency and different expression
levels. Furthermore, it displayed bands in western blotting bigger than the truncated
receptor. Based on those results, Bellatrix cells were chosen for further experiments.
On the one hand, FRET experiments to test the functionality with the Gi sensor, on
the other hand the preparation of supported membranes and click labelling. In en-
semble FRET experiments no signal was detected for Gi activation. As seen by TIRF
experiments before, the expression level and transfection efficiency could greatly differ.
Furthermore, it was not possible to check the cells simultaneously for co-expression of
Gi sensor and the full length receptor. For this reason, ensemble FRET experiments
were repeated with HEK cells transfected with Gi sensor, the Bellatrix plasmid and the
tRNA/synthetase. The expression of full length receptor was checked again by SNAP
labelling with SNAP SiR. SNAP SiR was chosen as control labelling because it exhibits
the lowest spectral overlap with the CFP/YFP FRET pair of the Gi sensor. If the
transfection efficiency was high enough, cells were measured at the FRET set-up for Gi
activation after stimulation with noradrenalin. A few cells showed very small responses
but nothing comparable to the positive control of the wild-type α2AAR . At the FRET
set-up it was not possible to check each cell individually for co-expression of the full
length receptor and the Gi sensor. This could explain why just a few cells showed any
response. The comparably small response might be due to the low expression levels of
the full length receptor. The positive control with wild-type α2AAR had far higher ex-
pression levels. Additionally, the western blot showed that the majority of receptors are
truncated even after transfection of tRNA/synthetase. A high over-expression, which is
needed for ensemble FRET experiments, was not achieved.
The low expression levels of full length receptor could serve as an advantage for the
smFRET experiments. Accordingly, click labelling was tested on supported membranes.
The preparation of supported membranes is on a normal coverslip successful for around
10 % of the cells, thus being a limiting factor for further experiments. As a consequence,
cells were tested beforehand for high transfection efficiencies. The transfection efficiency
turned out to be another limiting factor as only one transfection reached an efficiency of
10− 20 %. From this experiment supported membranes were prepared and immediately
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click labelled with TAMRA. The dye caused a high background because of unspecific
binding. Moreover, the dye labelled several intact cells, not supported membranes, in-
dicating that the dye is cell-permeable, at least to a certain degree. Interestingly, the
fraction of cells labelled with TAMRA via click chemistry was higher than the fraction
observed with SNAP SiR before. This is in agreement with the findings from the western
blot, showing several fragments longer than the truncated receptor. It seems that the
receptor is translated beyond the introduced amber codon in the 3ICL but only rarely
until the C-terminal SNAP-tag.
To confirm this hypothesis, further experiments would be needed as well as further im-
provements in the transfection efficiency for the full length receptor. Parameters that
could be tested for better transfection efficiency include the timing as well as the coating.
The cell density and the amount of plasmid was tested and optimised already. Further
perspectives for this project will be developed in the outlook, chapter 8.
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Opioid receptors play a key role as analgesic drug targets. However, the current drugs
have major side effects which also led to the so called ’opioid crisis’ in the US. A better
understanding of the receptor function is essential for the development of new, and im-
provements of current drugs. In order to achieve this, a better understanding of receptor
dimerisation is needed. Single-molecule microscopy has previously proven to serve as a
good measure to address dynamic dimerisation for different GPCRs. In this study a
novel set of fluorescent ligands targeting the MOR or the DOR was used to investigate
the diffusion behaviour of those receptors at a single-molecule level. In the case of the
MOR homodimerisation was examined.
Accordingly, it would be logical to continue this investigation by using the DOR lig-
ands to explore the dimerisation of the δ subtype. The results of such a study could
be compared to the findings of MOR. Our collaboration partner Antonios Drakopoulos
has used the same approach to study the KOR using fluorescent antagonists. Interest-
ingly, in the case of KOR no dimerisation beyond random colocalisation was observed
(unpublished data). With such a different behaviour for two different subtypes it would
be intriguing to compare the behaviour of the third subtype as well.
On the long-term, it would be fascinating to expand the set of fluorescent ligands to
have different types of ligands, e.g. full agonist, partial agonist and antagonist. Thus, it
would allow to directly compare the effect on the diffusion and also on a possible dimer
formation.
Likewise, it would be useful to use this new characterised set of subtype specific fluo-
rescent ligands, available for all three subtypes, to also investigate heterodimerisation at
a single-molecule level. A study by He et al. showed that heterodimerisation influences
the internalisation and trafficking of opioid receptors. [53] Gomes et al. showed that
heterodimerisation also alters the pharmacological response to ligands. [66] Thus, single-
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molecule approaches can help to characterise the effects of homo- and heterodimerisation
and to understand the different pathways that are triggered. With this understanding
it could be feasible to reduce unwanted side effects, paving the way for safer pain killers.
Heterodimerisation could be investigated with two different approaches. First, one could
use the set of fluorescent ligands at hand and choose different fluorophore for the different
sub-type. This way one would compare obtained colocalisations with random colocali-
sations, as this study did for MOR homodimers. A second approach would require the
synthesis of dual ligands that combine two ligands, each for one sub-type. However, with
dual ligands it could be more critical to conclude if the heterodimerisation is elevated by
their nature, meaning that once one side of the ligand binds to one receptor, the second
moiety recruits a second receptor.
In addition, the use of fluorescent ligands has the advantage that the targeted receptor
does not need to be genetically changed. Accordingly, the ligands could be used for
studies on wild-type opioid receptors in brain slices or primary cell cultures like neurons.
Especially helpful in this case is the high subtype selectivity and affinity of the presented
ligands. It would be worthwhile to compare the applicability of the fluorescent ligands to
methods using antibodies for fluorescent staining (especially for imaging). For fluorescent
ligands only one labelling step is needed in comparison to two steps with the use of
primary and secondary antibodies.
On the long term, if the fluorescent ligands can be further improved and the application
to primary cells or even tissue samples is successful, they could be used as reporter
for cancer detection. Singleton et al. have shown an elevation of MOR expression in
metastatic lung cancer. [134] As fluorophores have a low penetration depth in tissues,
the fluorophore moiety might need to be replaced in this case.
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In the case of the smFRET project on α2AAR , some questions need to be solved
and improved. A first step would be the improvement of expression of the full length
receptor in Bellatrix cells, as this will be needed for all further experiments. The first
trials for the incorporation of the unAA were promising, and labelling of the full length
receptor was successful on several occasions. However, it was still too low to pursue
preparation of supported membrane, or for functional tests using ensemble FRET or
the Gi sensor. Both an increased transfection efficiency and higher expression levels of
full length receptor, could improve the detection in western blots. In the best case, two
distinct bands can be detected, corresponding to the truncated receptor (stopped at the
amber codon) and the second band for the full length receptor.
For the smFRET protocol further improvements in the signal-to-noise ratio would be
desirable. Different possibilities arise.
i) The smFRET buffer could be improved to be less toxic for the cells or supported
membranes.
ii) More time could be dedicated to attempt further improvements and shorten the whole
protocol. The preparation of supported membranes, apyrase treatment, labelling with
two dyes, washing, mounting and sealing with smFRET buffer takes a long time. How-
ever, supported membranes are not very stable for a long time period.
iii) It was suggested to add a small amount of ethanol to the imaging buffer, as this
could improve the signal-to-noise-ratio, even though this would increase the toxicity.
iv) Since the beginning of my PhD project, more dyes for SNAP and CLIP labelling
became commercially available. Accordingly, new combinations of FRET pairs could be
tested.
Last but not least, the extraction of smFRET intensities was achieved but the signal-
to-noise ratio was too low for further analysis. If the signal-to-noise ratio could be
improved, more elaborate data processing would be needed. In this regard, the use of
a Hidden Marcov Model was envisioned. This would allow to determine the number of
substates without making a priori assumptions, reducing the bias.
If the method becomes reliably established, it will help to improve our understanding
of the activation process of α2AAR . Additionally, it could be applied to other receptors,
leading to more general knowledge. The effect of different ligands can be investigated
more directly, not just at a downstream level. It might be that different substates of the
receptor favour different pathways. Accordingly, different substates could be specifically
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8. Outlook
targeted in the drug development. It is important to note that smFRET experiments
were until now performed on purified or reconstituted receptors, but not in their native
environment. Consequently, the results found with purified receptors could be validated
by smFRET on supported membranes or even living cells.
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9. Appendix
9.1. Plasmid maps
SNAP 1540..2082
CLIP 991..1532
CD86 2089..2922
flag 961..982
Figure 9.1.: Plasmid map of CD86 with N-terminal SNAP- and CLIP-tag.
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Ha tagAlpha2A 933..2282
K327 amber 1911..1913
SNAP 2289..2831
Figure 9.2.: Plasmid map of the K327amber mutation of α2AAR. The stable cell line bearing
this plasmid is called ‘Bellatrix’.
SNAP 2289..2834
S347 Amber 1971..1973
Ha-Alpha2A 933..2282
Figure 9.3.: Plasmid map of the S347amber mutation of α2AAR. The stable cell line bearing
this plasmid is called ‘Capricorni’.
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9.1. Plasmid maps
S360 amber 2010..2012
SNAP 2289..2834
Ha-Alpha2A 933..2288
Figure 9.4.: Plasmid map of the S360amber mutation of α2AAR. The stable cell line bearing
this plasmid is called ‘Deneb’.
SNAP 2289..2834
k370 amber 2040..2042
HA- Alpha2A 933..2282
Figure 9.5.: Plasmid map of the K370amber mutation of α2AAR. The stable cell line bearing
this plasmid is called ‘Enif’.
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ha Alpha2A 933..2282
T373 Amber 2049..2051
SNAP 2289..2834
Figure 9.6.: Plasmid map of the T373amber mutation of α2AAR. The stable cell line bearing
this plasmid is called ‘Fafnir’.
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